



The Voice of Transplantation in the UK



ASSOCIATION OF BRITISH CLINICAL DIABETOLOGIST AND RENAL ASSOCIATION GUIDELINES
ON THE DETECTION AND MANAGEMENT OF DIABETES POST SOLID ORGAN
TRANSPLANTATION

ABCD-RA DIABETIC NEPHROPATHY CLINICAL SPECIALITY GROUP

Tahseen A Chowdhury MD, FRCP, Consultant in Diabetes, Royal London Hospital, London

Mona Wahba MA, FRCP, Consultant Nephrologist, St Helier Hospital, Carshalton

Ritwika Mallik MBBS, DNB, MRCP (UK), Specialist Registrar in Diabetes, Royal London Hospital, London

Javeria Peracha MB ChB, MRCP (UK), Specialist Registrar in Nephrology, University Hospitals Birmingham NHS Trust

Dipesh Patel PhD, FRCP, Consultant Physician, Diabetes & Endocrinology, Royal Free NHS foundation Trust, Honorary Associate Professor, UCL

Parijat De MBBS, MD, FRCP, Consultant Diabetologist, City Hospital, Birmingham

Damian Fogarty BSc, MD, FCRP, Consultant Nephrologist, Belfast Health and Social Care Trust, Belfast

Andrew Frankel MD, FRCP, Consultant Nephrologist, Imperial College Healthcare NHS Trust, London

Jannaka Karraliede MBBS FRCP PhD, Consultant Diabetologist, Guys and St Thomas's NHS Foundation Trust, London

Patrick B. Mark MB ChB, PhD, Professor of Nephrology, University of Glasgow, Glasgow

Rosa M Montero MD (Res), MRCP, Consultant Nephrologist, Royal Berkshire NHS Foundation Trust, Reading

Ana Pokrajac MD, MSc, FRCP, Consultant Diabetologist, West Hertfordshire Hospitals NHS Trust, Watford

Sagen Zac Varghese FRCP (Endo), PhD, FHEA, MEd, Consultant Diabetologist, ENHIDE, Lister Hospital, Stevenage

Steve C Bain MA, MD, FRCP, Professor of Medicine (Diabetes), University of Swansea, Swansea

Indranil Dasgupta DM, FCRP, Consultant Nephrologist, Heartlands Hospital, Birmingham. Warwick Medical School, Warwick

Debasish Banerjee MD FHEA FASN FRCP, Consultant Nephrologist, Renal and Transplant Unit, St George's University Hospital NHS Foundation Trust, London

Peter Winocour MD, FRCP (Glas), FRCP (Lond), Consultant Diabetologist, ENHIDE, QE2 Hospital, Welwyn Garden City

Adnan Sharif MD, FCRP, Consultant Nephrologist, University of Birmingham

CONFLICTS OF INTEREST STATEMENTS

Tahseen A. Chowdhury - None

Mona Wahba - None

Ritwika Mallik – None

Javeria Peracha - None

Dipesh Patel - has received honoraria for advisory work and/or lecture fees from AstraZeneca, Boehringer Ingelheim Eli Lilly, MSD and Napp Pharmaceuticals, Novo Nordisk and Sanofi.

Parijat De – has received speaker honoraria from Novo Nordisk, Lilly, Sanofi, Napp, Boehringer- Ingelheim, Astra, Pfizer

Damian Fogarty – declares speaker honoraria from Vifor, Napp & Pharmacosmos.

Andrew Frankel – declares receipt of research grants, preparation of educational materials and attendance at drug advisory boards for Astra-Zeneca, Boehringer Ingelheim/Lilly Alliance, Merck-Sharpe and Dohme, Napp Pharmaceuticals Ltd and Novo Nordisk

Jannaka Karraliede - has received honoraria for delivering educational meetings and/or attending advisory boards Boehringer Ingelheim, Astra Zeneca, Sanofi, Janssen, Novo Nordisk. Research grants from: Astra Zeneca, Sanofi

Patrick B. Mark - reports speaker honoraria from Vifor, Astrazeneca, Janssen, Napp, Novartis; research grants from Boehringer Ingelheim and non-financial support from Pharmacosmos

Rosa M Montero – None

Ana Pokrajac - non-promotional speaker fees, advisory boards and conference attendance by NAPP and NovoNordisk and Ellie Lily-BI Alliance

Sagen Zac Varghese- None

Steve C. Bain – reports honoraria, teaching and research sponsorship/grants from AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co, GlaxoSmithKline, Merck Sharp & Dohme, Novo Nordisk, Roche, Sanofi-Aventis, funding for development of educational programs from Cardiff University & Medscape. He owns a share of Glycosmedia and has provided expert advice to the All-Wales Medicines Strategy Group and National Institute for Health and Care Excellence (NICE) UK.

Indranil Dasgupta - None

Debasish Banerjee - None

Peter Winocour - has received honoraria for delivering educational meetings and/or attending advisory boards for Astra Zeneca, Boehringer Ingelheim, Eli Lilly, MSD, Napp, Sanofi, Novo and Vifor Pharmaceuticals

Adnan Sharif – reports advisory boards for Boehringer Ingelheim, Eli Lilly, Sandoz, Astellas, Atara Biotherapeutics, Novartis, honoraria and grant funding from Chesi, Napp Pharmaceuticals, Eli Lilly and travel reimbursement from Sandoz, Novartis.

Evidence grades for the recommendations

The following evidence grading has been used to determine the strength of the recommendations; the suggested audit standards; and the questions for areas that require future research.

1A – Strong recommendation: high-quality evidence

1B – Strong recommendation: moderate-quality evidence

1C – Strong recommendation: low-quality evidence

1D – Strong recommendation: very low-quality evidence

2A – Weak recommendation: high-quality evidence

2B – Weak recommendation: moderate-quality evidence

2C – Weak recommendation: low-quality evidence

2D – Weak recommendation: very low-quality evidence

Search strategy

The recommendations are based on a systematic review of the Cochrane Library, PubMed/MEDLINE, Google Scholar and Embase, using the following key words: new onset diabetes after transplantation, post-transplant diabetes, renal transplant and diabetes, liver transplant and diabetes, cardiac transplant and diabetes

Review date: March 2022

TABLE OF CONTENTS

SUMMARY OF RECOMMENDATIONS

1.0 INTRODUCTION

2.0 EPIDEMIOLOGY OF PTDM

3.0 PATHOGENESIS OF PTDM

4.0 DETECTION OF PTDM

5.0 MANAGEMENT OF PTDM

6.0 MODIFICATION OF IMMUNOSUPPRESSION TO PREVENT OR TREAT PTDM

7.0 PREVENTION OF PTDM

8.0 PTDM CONSIDERATIONS IN THE NON-RENAL SETTING

SUMMARY OF RECOMMENDATIONS

EPIDEMIOLOGY

1. Data relating to diagnosis of PTDM using specific diagnostic criteria should be routinely collected for accurate auditing of incidence, prevalence and outcomes in all transplant centres (Ungraded).
2. Micro- and macrovascular outcome data for solid organ transplant recipients with PTDM should be collected (Ungraded)

PATHOGENESIS

1. Counselling of risk for PTDM should consider individualised risk factors (Grade 1B).

DETECTION

1. Avoid diagnosis of PTDM in the first six weeks post operatively when transient hyperglycaemia is extremely common (Grade 1B).
2. Afternoon capillary blood glucose monitoring (AGM) is recommended to identify patients with post-operative hyperglycaemia. These patients need close monitoring and formal testing for PTDM when clinically stable (Grade 1B).
3. A formal diagnosis of PTDM can be made from six weeks post-transplantation using an oral glucose tolerance test (Grade 1B).
4. Oral glucose tolerance test is the current gold standard for diagnosis of PTDM. While it may not be practical to use routinely in all solid organ transplant recipients prospectively, it should be utilised when possible for additional risk stratification and/or diagnostic clarification (Grade 1B).
5. HbA_{1c} ≥6.5% (48mmol/L) is a suitable diagnostic test in clinically stable solid organ transplant recipients after the first three months post-transplantation. In asymptomatic patients, the test should be repeated after two weeks to confirm the diagnosis (grade 1B).
6. Caution with the use of HbA_{1c} must be exercised in the presence of factors that may impair accurate interpretation (Grade 1A).

7. In stable patients combining the results from abnormal fasting plasma glucose (FPG) $\geq 7\text{mmol/L}$ and/or $\text{HbA}_{1c} > 6.5\%$ (48mmol/mol) will detect the majority of PTDM cases (Grade 2C).
8. Patients awaiting transplant should receive annual glycaemic testing with FPG +/- HbA_{1c} . High risk patients should then go on to have OGTT to confirm diagnosis of diabetes or screen for impaired glucose tolerance (Grade 2C).
9. The use of novel diagnostic tools such as fructosamine and glycated albumin are undetermined and cannot be recommended as clinical tools (Grade 2D)

MANAGEMENT

1. Immediately post-transplant, early post-operative hyperglycaemia (glucose $> 11\text{mmol/L}$ on two occasions within 24 hours) should be actively monitored and treated. If hyperglycaemia is mild ($< 14.0\text{mmol/L}$), then oral hyperglycaemic therapy can be considered. Otherwise, early insulin therapy should be instituted either intravenously or subcutaneously (Grade 1C).
2. Glycaemic target for people with PTDM should be around 7% (53mmol/mol), but adjusted according to degree of chronic kidney disease, age, co-morbidity, ability to self-manage, and patient preference (Grade 1B).
3. All people with a confirmed diagnosis of PTDM should be offered structured diabetes education (Grade 1B).
4. The diagnosis of PTDM must be conveyed to the patients' usual primary care practitioner, and the patient should be put on to a diabetes register (ideally coded as post-transplant diabetes mellitus), and offered structured diabetes care, along with regular screening for complications (Grade 1B).
5. If patients with a stable $\text{eGFR} \geq 30\text{mls/min/1.73m}^2$ and $\text{BMI} \geq 25\text{kg/m}^2$, metformin should be considered first line oral therapy for people with confirmed PTDM (Grade 1C).
6. Other therapies which may be used safely in PTDM include sulfonylureas, meglitinides, DPP-4 inhibitors, pioglitazone and GLP-1 analogues. Use of sulfonylureas and meglitinides should be undertaken with care especially in those at risk of hypoglycaemia, and doses should be adjusted according to eGFR (Grade 2C)
7. SGLT-2 inhibitors should be used with caution in patients with stable $\text{eGFR} \geq 30\text{mls/min/1.73m}^2$ and poor glycaemic control in patients at low risk of urinary

tract infection, after careful discussion with nephrology and diabetes specialists (Grade 1C).

8. Insulin therapy should be considered in all patients who have inadequate glucose control, or who have symptomatic hyperglycaemia (Grade 1C).
9. Blood pressure should be controlled below 130/80 mmHg in all people with PTDM (Grade 1B).
10. All people with PTDM should be offered statin therapy, irrespective of cholesterol level (Grade 2D).
11. All people with PTDM should have access to specialist diabetes expertise within a multidisciplinary team setting (Grade 1C).

MODIFICATION OF IMMUNOSUPPRESSION

1. Whilst immunosuppression is a major risk factor for PTDM, any planned modification to attenuate this risk should be balanced against the risk for allograft rejection (Grade 1B).
2. Individualisation of immunosuppression based on the recipient's immunologic and glycaemic risk must be taken as part of an overall strategy to improve long term transplant outcome (Grade 1C).
3. Until further evidence emerges, we adopt the recommendation that the choice of immunosuppressive therapy should be primarily to prevent rejection rather than preventing PTDM (Grade 1C).
4. There is no evidence to suggest changing immunosuppressive therapy when hyperglycaemia is detected has a role in the management of PTDM (Grade 2B).
5. There is as yet no evidence that newer agents such as belatacept are beneficial in reducing risk of PTDM compared to tacrolimus-based regimens (Grade 1C).

PREVENTION

1. The risk for development of diabetes should be assessed as part of a pre-transplant work-up for all people being considered for transplantation (Grade 1B).
2. All people awaiting transplantation should be educated on the risk of developing PTDM, should be counselled about minimising weight gain using lifestyle measures, and should see a dietitian with expertise in this area (Grade 1B).

3. Treatment of risk factors for PTDM such as hepatitis C should be considered in patients awaiting transplantation (Grade 1C).
4. In people considered at high risk for the development of PTDM, consideration should be given to immunosuppressive therapy that is less prone to inducing hyperglycaemia, but this should be based on individualised risk with immunological status in mind (Grade 1C).
5. All patients deemed at high risk for development of PTDM should be screened yearly for diabetes whilst awaiting transplantation (Grade 1B).

CONSIDERATIONS IN THE NON-RENAL SETTING

1. Organ-specific factors should be considered when counselling patients for their risk of PTDM prior to solid organ transplantation (Grade 1B).
2. The diagnosis of PTDM should be consistent across different solid organ transplant settings, with organ-specific caveats in mind to determine the optimal diagnostic test (e.g. accuracy of HbA_{1c}) (Grade 1C).
3. The management of PTDM should be consistent across different solid organ transplant settings, with organ-specific caveats in mind to determine the optimal management strategy (Grade 1B).

1.0 INTRODUCTION

Since the first successful renal transplant between identical twins in Boston in 1954, this modality of renal replacement therapy has improved the lives of millions of people with end stage renal disease (ESRD) worldwide. In the UK in 2017/8 there were 4,757 patients awaiting renal transplantation, and 3,272 renal transplants were undertaken [1]. The benefits of renal transplantation on morbidity and mortality in patients with chronic kidney disease (CKD) are well described. In the UK, the 10-year survival for recipients of living kidneys is 90%, whilst recipients of kidneys from deceased donation after brain or cardiac death have 10-year survival of 77% and 74% respectively [1]. By contrast, 10-year survival for patients on haemodialysis starting at the age of 55-64 years is significantly worse at around 30% [1]. Furthermore, solid organ transplantation (SOT) for patients with end organ failure is a well-established and life-saving treatment.

Whilst diabetes mellitus (DM) is recognised as the most important cause of ESRD worldwide [2-4], in people who do not have diabetes, a high risk for the development of dysglycaemia post-transplant has been recognised for over 50 years. Post-Transplant Diabetes Mellitus (PTDM), previously termed New Onset Diabetes after Transplantation (NODAT) was first recognised after liver transplantation by Starzl and colleagues in 1964 [5]. The condition is defined as the presence of DM first recognised following SOT. The condition has been suggested to affect between 10% and 40% of patients undergoing SOT. It is clear that hyperglycaemia post-transplant has a significant adverse impact on renal and other outcomes. As people live longer with transplants, cardiovascular morbidity and mortality becomes more prevalent, and PTDM appears to be an important risk factor for these complications.

PTDM results from similar risk factors to that of Type 2 diabetes (T2D), but in addition, specific transplant related factors have an important role. The aim of this guideline is to focus specifically on dysglycaemia or DM recognised primarily after transplantation. We recognise, however, that a number of people with PTDM may well have undetected pre-transplant DM. Indeed, the term NODAT was changed to PTDM by a Consensus report in 2014, to reflect the time of diagnosis rather than the time of onset [6]. As most data on PTDM exists in renal transplantation, we aim to focus on this area, but also include some data on other SOT that may add to the present evidence / knowledge base. While these

recommendations focus on the topic of PTDM in non-diabetic solid organ transplant candidates and recipients, they are also of relevance for SOT recipients with pre-existing diabetes who may suffer glycaemic deterioration post-transplantation.

We aim to review the definition of PTDM, and the evidence behind screening, diagnosis, hyperglycaemic and immunosuppressive management, and discuss potential methods for prevention of the condition. In each section, we aim to produce evidence graded recommendations, areas for further research and audit standards.

2.0 EPIDEMIOLOGY OF PTDM

2.1 Recommendations

1. Data relating to diagnosis of PTDM using specific diagnostic criteria should be routinely collected for accurate auditing of incidence, prevalence and outcomes in all transplant centres (Ungraded).
2. Micro- and macrovascular outcome data for solid organ transplant recipients with PTDM should be collected (Ungraded)

2.2 Areas for future research

1. Determine the incidence of PTDM longitudinally post-transplantation among different patient cohort groups (eg. age, gender, body mass index, ethnicity).
2. How does the standardised incidence ratio differ for development of diabetes comparing a transplant versus general population cohort?
3. What are the long-term outcomes associated with PTDM across different population cohorts?
4. Does progression of micro- and macrovascular complications differ for patients with PTDM compared to other forms of diabetes mellitus?
5. Do micro- and macrovascular outcomes differ for patients with PTDM compared to other forms of diabetes mellitus?
6. Is the epidemiology of PTDM changing in the contemporary climate of solid organ transplantation?

2.3 Audit recommendations

1. What proportion of PTDM patients are recorded correctly in hospital and primary care records?
2. What proportion of patients with PTDM have regular screening for microvascular complications of diabetes?

2.4 Overview

Understanding the epidemiology of PTDM has been complicated by the lack of clear diagnostic criteria, with harmonisation of diabetes classification with the general population only occurring with the original Consensus guidelines published in 2003 [1]. While this aided understanding in both the incidence and prevalence of PTDM, we still lack a clear understanding of long-term outcomes related to PTDM. The study of PTDM has primarily been conducted in the setting of kidney transplantation, but some of the risk factors for development of PTDM will be shared with other solid organ transplant setting and will be discussed further in Section 8.

2.5 Incidence and prevalence of PTDM

Prior to 2003, the reported incidence and prevalence of PTDM varied significantly and reflected heterogeneous clinical practice. Different immunosuppressive regimens, mixed diagnostic criteria and diverse transplant cohort demographics meant incidence and prevalence rates reported by different centres were not comparable to other units. In the era of glucocorticoids and azathioprine, the incidence of DM was reported in up to 50% of recipients [2], but introduction of calcineurin inhibitors (CNIs) (first ciclosporin and then tacrolimus), with a shift to more steroid-sparing exposure, reported rates of PTDM declined, but were still incredibly variable between 2% to 53% due to the lack of uniform diagnostic practice [3]. This prompted the 2003 Consensus meeting to formulate guidelines to achieve a standard of care for diagnosis, prevention and management of PTDM [1].

Utilising contemporary diagnostic criteria for PTDM in the publication of the original Consensus guidelines, a clearer picture of the scale of dysglycaemia after SOT is being ascertained. However, even in studies using the current consensus criteria, the reported incidence of PTDM can still vary between 9% and 39% in the first-year post-transplantation [4], and likely reflects distinct patient demographics and immunosuppression practice. Beyond the first year after transplantation, it is difficult to determine whether the incremental risk of developing PTDM is over and above the risk compared to the general population. However, with increasing longevity of both transplant recipients and their allograft, the presumption is the cumulative exposure to diabetogenic risk factors (both traditional and transplants-specific) leads to increased risk for PTDM. For example, the

incidence of *de novo* PTDM after 20 years of kidney graft survival is reportedly low at only 8% in a Northern Irish cohort (n=706) transplanted between 1968 and 1993 [5]. The diagnostic criteria for PTDM was, however, the need for oral hypoglycaemic or insulin therapy, and therefore is likely to significantly under-estimate the true incidence.

A controversial issue is whether the incidence of PTDM is declining. There are many putative explanations for this; increased awareness, rationalised immunosuppression, reduced rejection rates. For example, contemporary immunosuppression regimens across the majority of transplant centres adopt CNI-sparing regimens (to avoid the risk of associated nephrotoxicity) and such strategies to reduce exposure to tacrolimus or ciclosporin are associated with significantly reduced risk of developing PTDM [6]. In a Norwegian single-centre analysis of patients undergoing oral glucose tolerance testing (OGTT) at 10-weeks post-transplant, the odds of developing PTDM appear to have halved between 1997 and 2007 [7]. While abnormal glucose metabolism developing beyond 10 weeks may have been undetected, repeat testing of this cohort at six years found an increase in kidney transplant recipients with a normal oral glucose tolerance test (OGTT) from 46% to 65% [8]. Data from the United States Annual Data Report also documents a fall in the incidence of PTDM at 1-, 3- and 5-years after kidney transplantation over the last decade, though it is unclear if the same definition of DM was maintained throughout (17). Work from Porrini and colleagues, has demonstrated a bimodal distribution to the incidence of PTDM and implies a cumulative increase in long-term risk for surviving transplant recipients [9].

One of the reasons for a lack of clarity in the data relates to the absence of inclusion of PTDM as part of routine returns to transplant registries. Such additional information will facilitate a greater understanding of the long-term impact of PTDM, which currently is limited to published literature from single-centre studies rather than a population-cohort study using robust diagnostic criteria.

2.6 Impact of PTDM on long-term mortality

PTDM has shown to be associated with increased risk for mortality after transplantation, although there is some inconsistency in the literature with regards to long-term mortality. The majority of studies report PTDM to be independently associated with increased risk for mortality after kidney transplantation [10-15], but other studies have reported no

association between PTDM and patient survival [16, 17]. There are, however, limitations to these studies that skew our interpretation of the long-term impact of PTDM. For example, some studies have only found an association between PTDM and mortality if individuals were taking glucose-lowering therapy [10]. Eide and colleagues only observed a mortality risk for kidney transplant recipients with PTDM based on glucose-based diagnostic criteria rather than the use of glycated haemoglobin (HbA_{1c}) for diagnosis [11]. Studies showing no association between PTDM and mortality may be limited by short duration of follow up. For example, Gaynor and colleagues who demonstrated no link between new-onset diagnosis of PTDM with risk for mortality had follow up to 56-months only [16]. Kuo and colleagues also demonstrated no link between PTDM and mortality but had follow up to 36-months [17]. The lack of robust data collection by national transplant registries for PTDM is a major limiting factor to accurately assess the impact of PTDM on mortality and needs rectifying.

2.7 Impact of PTDM on long-term graft loss

The association between PTDM and graft loss is less clear. While an association with overall graft loss is well recognised (driven by mortality), the association between PTDM and death-censored graft loss is more ambivalent [12]. Cole and colleagues, in their analysis of the United States Renal Data System (USRDS) registry, observed a similar impact of PTDM and acute rejection on risk for overall graft loss due to different mechanisms; PTDM was associated with increased risk for mortality but not death-censored graft loss while rejection had a contrasting effect [15]. The worst overall outcome existed for patients who developed both rejection and PTDM, similar to finding from Matas and colleagues [18]. Valderhaug and colleagues also observed an association between PTDM (based upon 2-hour postprandial glucose) and overall graft loss but not death-censored graft loss [19].

2.8 Impact of PTDM on morbidity and quality of life

Rejection remains the leading cause of patient concern [20], but the relationship between PTDM and rejection is not bi-directional. Treatment for allograft rejection includes large corticosteroid boluses, which is consistently shown to be a risk factor for PTDM, but it is unclear if PTDM leads to an increased risk for rejection. While pre-existing diabetes at the time of kidney transplantation has been associated with increased risk for rejection after

kidney transplantation [21], the data linking PTDM with increased subsequent risk for rejection is scarce.

Numerous publications have shown an association between PTDM and increased risk for cardiovascular events which likely is the leading contributor to the observed increase in mortality rates [22-24]. Review articles of cardiovascular disease after kidney transplantation consistently cite PTDM as a risk factor worthy of detection, prevention and management [25]. While it appears risk for cardiovascular events from PTDM may not be as high as pre-existing diabetes, this likely reflects the difference in cumulative exposure to glycaemia, or the presence of pre-existing metabolic syndrome, rather than PTDM having different prognostic implications for cardiovascular events.

Data in relation to microvascular complications are limited for PTDM. Burroughs and colleagues observed the emergence of diabetes-related microvascular complication after new-onset PTDM occurred in over half of kidney transplant recipients within three years of follow up [26]. Median time to onset of microvascular complications was approximately 1.8 years, contrasting sharply with the general population [26]. However, this contrasts with recent data from Londero and colleagues who analysed 64 kidney transplant recipients with PTDM of at least 5-years duration (mean duration of 8-years) [27]. They observed a lower than expected prevalence of microvascular complications, with no evidence of any diabetic retinopathy but more evidence of neuropathy (e.g. distal symmetric polyneuropathy) [27].

There is no published work exploring quality of life for SOT recipients who develop PTDM. Qualitative work from kidney transplant recipients in Australia cites development of diabetes after transplantation as a leading concern [20], but no work has explored quality of life parameters for patients with versus without PTDM. The need for diabetes therapies, plus additional monitoring is likely, however, to have an adverse effect on quality of life.

3.0 PATHOGENESIS OF PTDM

3.1 Recommendations

1. Counselling of risk for PTDM should consider individualised risk factors (Grade 1B)

3.2 Areas for future research

1. Clarify risk factors for development of PTDM in context of uncertain or conflicting published literature (e.g. risk for PTDM with polycystic kidney disease)
2. Does the pathophysiology of early onset PTDM differ from late-onset PTDM?
3. What contribution do individual risk factors make as part of the combined risk for PTDM?
4. Is a stratified approach to high-risk patients for diagnosis, prevention and/or management effective to prevent PTDM?
5. How can the pre-transplant genetic risk for PTDM be utilised in a clinical application to reduce risk?

3.3 Audit recommendations

1. What proportion of patients are informed of their risk for developing PTDM whilst awaiting transplantation?

3.4 Overview

PTDM must be considered as a distinct metabolic entity from other forms of DM, and its' pathogenesis reflects this separation. This is an important distinction as an increased understanding of the drivers for the development of PTDM could lead to more targeted intervention for prevention and management. While SOT recipients have the same generic risk factors for DM as the general population, their additional exposure to unique transplant-specific risk factors is a key factor that leads to the significant burden of PTDM.

3.5 Risk factors for PTDM

Risk factors for the development of PTDM are well documented [1,2]. Risk factors can be categorised as non-modifiable versus modifiable, or generic versus transplant-specific, and are summarised in Table 1 below.

Table 1. Current understanding or risk factors for PTDM

Non-modifiable	Modifiable
<ul style="list-style-type: none">• Age• Ethnicity<ul style="list-style-type: none">– Black– Hispanic– South-Asian• Family history of diabetes mellitus• Cause of end-stage renal failure<ul style="list-style-type: none">– Polycystic kidney disease• Gender• HLA mismatch• Deceased-donor kidney• Genetics• Innate immunity	<ul style="list-style-type: none">• Previous stress related hyperglycaemia• Obesity• Metabolic syndrome• Pre-transplant triglycerides• Cytomegalovirus• Hepatitis C• Immunosuppression<ul style="list-style-type: none">– Tacrolimus– Ciclosporin– Sirolimus– Corticosteroids– Basiliximab• Rejection episodes• Anti-hypertensive medications<ul style="list-style-type: none">– Beta blockers– Thiazide diuretics• Reduced glomerular filtration rate

While some risk factors are well acknowledged (age, ethnicity, immunosuppression), others are more speculative with conflicting evidence. For example, data is conflicting as to whether adult polycystic kidney disease (APKD) is a risk factor for PTDM, with published studies showing either a positive [3,4] or negative [5-7] association. A recent meta-analysis of all published cohort studies did suggest that the pooled empirical data demonstrates an association between APKD and PTDM [8]. However, heterogeneous study cohorts with poorly defined PTDM means the data may not translate across all populations.

Understanding the underlying risk profile can help risk stratify, and to appropriately counsel kidney transplant recipients of their risk for developing PTDM, facilitating additional support or pre-emptive modifications to peri- and/or post-transplant management to attenuate the risk for developing PTDM. However, such proactive approaches need to be tailored to the individual and based on evidence.

3.6 Pathophysiology of PTDM

Underlying risk factors have an important role in the development of PTDM and partially explain our increasing understanding of the pathophysiology of PTDM, which supports its distinction as a separate metabolic entity from other forms of diabetes.

3.6.1 General pathophysiology of DM

Type 1 Diabetes (T1D) is well recognised to be an autoimmune disorder characterised by the destruction of insulin-producing pancreatic β -cells, whilst T2D is characterised by a combination of declining insulin secretion in the presence of insulin resistance [9]. Variation in β -cell insulin secretion, as a response to the state of insulin resistance, is controlled by changes in the secretory capacity of the β -cell and not as a direct influence of glucose [10]. This hyperbolic relationship also implies the existence of a feedback loop mechanism: for glucose metabolism to remain constant the β -cell has to have the ability to make proportionate and reciprocal alterations to insulin secretion in the context of variable insulin sensitivity. Further work is required to determine the mechanism of this feedback loop, but it appears that glucose may not be alone in mediating this regulation [11]. Abnormalities of the β -cell occur before the onset of hyperglycaemia. β -cell dysfunction begins as a response to the state of insulin resistance, with a compensatory increase in insulin secretion to

maintain the physiological constant to control glucose metabolism. Further decline in insulin sensitivity leads to further compensatory measures by the β -cell to maintain this hyperbolic relationship. Throughout this period of physiological flux between insulin secretion and sensitivity, a state of normoglycaemia exists. The inability of the β -cell to secrete an adequate quantity of insulin in the state of insulin resistance heralds the onset of dysglycaemia and failure to attenuate this subsequently leads to the onset of T2D.

3.6.2 Pathophysiology of diabetes in setting of uraemia and/or liver dysfunction

Insulin secretion is not affected in uraemic subjects [12]. Rather, the uraemic state is associated with insulin resistance as a result of tissue insensitivity to the metabolic actions of insulin [40]. The primary site of insulin resistance resides in the peripheral tissue as opposed to either augmented hepatic glucose production or impaired hepatic glucose uptake [13].

Renal gluconeogenesis, and the dual contributions of the renal cortex and medulla to glucose homeostasis, is important in the pathophysiology of DM. It is speculated that 20-25% of glucose released into the circulation in the fasting state originates from the kidneys through gluconeogenesis [14]. Evidence to support a skewed balance of glucose utilisation versus release in the context of renal failure can be extrapolated from the observation that exogenous insulin requirements decrease in patients who develop ESRD [15]. One of the explanations for this phenomenon is the prolonged biological half-life of insulin due to a loss of renal insulin excretion [16]. However, the observation of hypoglycaemia in non-diabetic renal failure patients raises the possibility of decreased renal gluconeogenesis, secondary to a loss of renal cortex tissue, as an additional contributory factor [17]. This is supported by the findings suggesting the kidney plays an important role in glucose counter-regulation [18].

The concept of hepatogenous DM, defined as a state of impaired glucose regulation caused by loss of liver function due to cirrhosis, has long been recognised. Both β -cell dysfunction and insulin resistance are believed to contribute to its pathophysiology, with the latter believed to be the predominant defect [19]. However, many of these defects likely occur pre-cirrhotic stages and evidence suggests diabetes rates increase with worsening stages of cirrhosis [20], although this finding is not consistent [21]. Combined with underlying aetiology of liver disease, with some causes of liver dysfunction associated with an increased

risk for diabetes, the complex interplay between liver dysfunction and DM risk becomes an important yet poorly understood issue in the context of PTDM.

3.6.3 Pathophysiology of PTDM

The development of PTDM occurs in the context of declining insulin secretion in the presence of insulin resistance [22], which appears similar to T2D [23]. Many generic and transplantation-specific risk factors have been associated with the development of PTDM, as discussed above, which contribute to the underlying pathophysiology. However, a number of areas remain poorly understood in comparison to other forms of DM.

Hagen and colleagues conducted a six year prospective study assessing the change in glucose metabolism in renal transplant recipients [24]. They found a decline in insulin secretion was the dominant mechanism by which PTDM developed. They also documented that an improvement in insulin sensitivity could normalise glucose intolerance, and this fits in with the hyperbolic relationship previously discussed and the concept of the disposition index.

The role of CNIs in the pathogenesis of PTDM is well documented, with tacrolimus having a stronger association than ciclosporin for the condition [25-27]. Duijnhoven and colleagues examined the impact of tacrolimus on glucose metabolism prospectively using a frequently sampled, intravenous glucose tolerance test [28]. Tacrolimus commencement was associated with a significant decrease in the insulin sensitivity index as a result of diminished insulin secretion (there was no associated change in insulin resistance). Patients with abnormal insulin sensitivity indexes in this study appeared to be at greater risk of developing PTDM on longitudinal follow up. Tacrolimus trough level reduction from 9.5 to 6.4 ng/ml was shown to improve pancreatic β -cell secretion as assessed by C-peptide secretion (49.0 to 66.6 nmol.min/l, $p = 0.04$), although there was a borderline statistical significance for insulin secretion (1134 to 1403 mU.min/l, $p = 0.06$). It therefore appears likely the diabetogenicity of CNIs is dose-dependent and the clinical challenge is to achieve a balance between attainment of efficacy and minimisation of side effects.

CNIs are associated with the up-regulation of insulin gene expression, decreasing insulin synthesis by transcriptional inhibition of insulin mRNA [29]. In vitro and in vivo studies have

shown CNIs may also affect insulin secretion, in addition to inhibition of insulin synthesis, through reversible toxicity to the pancreatic β -cell [30]. Hirano and colleagues demonstrated the reversible toxicity of tacrolimus on rat islets; high dose treatment was associated with functional (impaired insulin secretion and reduced pancreatic insulin levels) and structural (vacuolation of the islets on histopathological examination) changes, which reversed by two weeks after cessation of the drug [31]. In addition, CNIs have also been suggested to have an influence on insulin sensitivity [29].

The role of glucocorticoids in development of PTDM also warrants mention. Glucocorticoids interfere with carbohydrate metabolism and insulin secretion and action via a number of mechanisms, including inducing insulin resistance by effects on insulin receptors in liver, muscle and adipose tissue.

While agreement exists that PTDM involves a combination of increased insulin resistance and β -cell dysfunction, the relative importance of each component remains debated. To the extent that insulin resistance may not manifest as hyperglycaemia after transplantation until pancreatic β -cells are unable to compensate, β -cell dysfunction is probably necessary for overt PTDM. No significant research has investigated changes in glucagon, incretin hormones or renal handling of glucose post-transplantation, although limited experience exploiting renal handling of glucose suggests a possible route of pharmacological intervention even in a transplant setting.

3.6.4 Unique aspects of PTDM pathophysiology

Elucidating the primary pathophysiological defect in PTDM is important as it may help prioritise a rational hierarchy of therapeutic intervention. However, it is more likely that pathophysiological mechanisms for the development of PTDM, and the relative contribution of various mechanistic components, will be heterogenous across different patient characteristics and time period post transplantation. A feature unique to PTDM is the magnitude of dynamic change in glucose metabolism, especially within the first few months post-transplant with the majority undergoing rapid reduction in overall immunosuppression burden or conversely a minority who require additional corticosteroids for acute rejection. Hyperglycaemia consistent with a diagnosis of DM is ubiquitous among renal transplant recipients within the first weeks post-transplant and there is evidence that hyperglycemia

requiring inpatient insulin therapy that improves is still associated with four fold increased risk for subsequent development of PTDM [30,31]. This bi-directional nature of glucose metabolism in the setting of solid organ transplantation is unique and clinically well demonstrated [21, 32].

Finally, PTDM is distinguished by the interplay of an unusually large number of generic and transplant-specific variables. Genetic polymorphisms may be important risk factor for PTDM and genome-wide association studies support the hypothesis that pancreatic β -cell dysfunction is critical in the development of PTDM, with a number of single-nucleotide polymorphisms identified in genes that are associated with β -cell apoptosis [33]. However, insulin resistance remains important and the metabolic syndrome (putatively with insulin resistance as the key pathophysiological defect) is prevalent after transplantation [34]. Current consensus is that pancreatic β -cell dysfunction is the predominant pathophysiological defect in early onset PTDM, with insulin resistance the major contributor to late onset PTDM and prospective cohort studies will be important to distinguish both pathophysiological and clinical features of different forms of PTDM.

4.0 DETECTION OF PTDM

4.1 Recommendations

1. Avoid diagnosis of PTDM in the first six weeks post operatively when transient hyperglycaemia is extremely common (Grade 1B).
2. Afternoon capillary blood glucose monitoring (AGM) is recommended to identify patients with post-operative hyperglycaemia. These patients need close monitoring and formal testing for PTDM when clinically stable (Grade 1B).
3. A formal diagnosis of PTDM can be made from six weeks post-transplantation using an oral glucose tolerance test (Grade 1B).
4. Oral glucose tolerance test is the current gold standard for diagnosis of PTDM. While it may not be practical to use routinely in all solid organ transplant recipients prospectively, it should be utilised when possible for additional risk stratification and/or diagnostic clarification (Grade 1B).
5. HbA_{1c} ≥6.5% (48mmol/mol) is a suitable diagnostic test in clinically stable solid organ transplant recipients after the first three months post-transplantation. In asymptomatic patients, the test should be repeated after two weeks to confirm the diagnosis (grade 1B).
6. Caution with the use of HbA_{1c} must be exercised in the presence of factors that may impair accurate interpretation (Grade 1A).
7. In stable patients combining the results from abnormal fasting plasma glucose (FPG) ≥7mmol/L and/or HbA_{1c} >6.5% (48mmol/mol) will detect the majority of PTDM cases (Grade 2C).
8. Patients awaiting transplant should receive annual glycaemic testing with FPG +/- HbA_{1c}. High risk patients should then go on to have OGTT to confirm diagnosis of diabetes or screen for impaired glucose tolerance (Grade 2C).
9. The use of novel diagnostic tools such as fructosamine and glycated albumin are undetermined and cannot be recommended as clinical tools (Grade 2D)

4.2 Areas for future research

1. Does method of PTDM detection impact upon long-term outcomes?

2. Do solid organ transplant recipients with transient hyperglycaemia post-transplant have an increased risk for future PTDM?
3. What are the long-term outcomes for solid organ transplant recipients with impaired fasting glucose, impaired glucose tolerance or pre-diabetes?
4. Does risk of PTDM differ for recipients with impaired fasting glucose versus impaired glucose tolerance?
5. Are there any additional benefits from fructosamine and/or glycated albumin as diagnostic tools for PTDM?

4.3 Audit recommendations

1. Is there a formal protocol for screening for pre-existing diabetes in people awaiting transplantation?
2. What proportion of patients are screened for hyperglycaemia in the immediate post-transplant period?
3. What proportion of patients following transplantation undergo yearly HbA_{1c} screening?

4.4 Overview

Current guidelines recommend the use of the term PTDM as opposed to NODAT, as the latter term implies that diabetes prior to transplantation has been adequately excluded.

There has been no clear definition of the criteria for PTDM diagnosis until the publication of the first PTDM consensus guidelines in 2003 [1]. This lack of uniform diagnostic criteria explains the heterogeneity in reported rates for PTDM incidence after kidney transplantation, ranging from as low as 3% to greater than 40% in the published literature [2,3]. Several older publications have used discharge with prescription of glucose-lowering therapies as the sole definition of PTDM, which leads to an underestimation of the true incidence of PTDM in historical publications. Therefore, the first consensus guideline from 2003 proposed to adopt the DM definition endorsed by the American Diabetes Association (ADA) at that time. Since the ADA guidelines for the diagnosis of DM have been subsequently revised, the most recent consensus guidelines for PTDM have taken these changes into account such as inclusion of HbA_{1c} as diagnostic tool for PTDM [4]. In parallel to the ADA recommendations, current PTDM guidelines emphasise the clinical relevance of pre-diabetes (impaired glucose tolerance [IGT] and impaired fasting glucose [IFG]), since both conditions are likely to confer increased risks for the development of PTDM, and IGT *per se* has been suggested as an independently predictor of mortality [5,6].

A further important issue that required resolution was the time-point after which PTDM should be officially diagnosed. The development of significant hyperglycaemia is ubiquitous among non-diabetic kidney transplant recipients in the immediate early post-operative phase [7,8]. Although early post-operative hyperglycaemia may be a risk-factor for subsequent development of PTDM, it should not be used as diagnostic criterion for PTDM since many cases are transient. This fact has been considered in the current guidelines which recommend that PTDM diagnosis should only be made in the later stable clinical period beyond the first six weeks after transplantation [4]. After this initial hyperglycaemic peak during the first few weeks after transplantation, the incidence of PTDM increases with time after transplantation [9] and has been shown to have a bimodal incidence risk [10].

4.5 Fasting plasma glucose (FPG)

FPG ≥ 7.0 mmol/L (126 mg/dL) is one criterion for the diagnosis of DM [11]. IFG (a pre-diabetic state) is defined by the ADA as FPG between 5.6 mmol/L (100 mg/dL) and 6.9 mmol/L (125 mg/dL), and the World Health Organisation (WHO) as 6.1 mmol/L (110 mg/dl) to 6.9 mmol/L (125mg/dL). Determination of FPG is a relatively easy and quick screening method for glucose homeostasis alterations but has several important limitations.

Isolated elevation of FPG is a consequence of hepatic insulin resistance with normal muscle insulin sensitivity and often is combined with defects in the early-phase insulin secretory response [12]. In non-transplanted subjects, IFG is much more common in men than in women and there may be little overlap with IGT [13]. In stable kidney transplant recipients, without a history of DM or pre-diabetes, the prevalence of isolated IFG has been reported to be between 12-18 %, isolated IGT was found in approximately 9%, and combined IFG/IGT in between 12-14% [14,15]. In the general population, sole determination of FPG would miss approximately one third of patients with DM who have an isolated defect in glucose tolerance [16]. In kidney transplant recipients, the situation is similar: 25-30% of patients with PTDM would be missed based solely upon isolated determination of PTDM using FPG [14,17]. Maintained FPG in the normal range despite IGT is also pathophysiologically linked to renal disease since reduced renal clearance of insulin predisposes to low FPG and elevated postprandial glycaemia [18].

Some transplant centres have utilised a hybrid approach and combined diagnostic tools by facilitating an oral glucose tolerance test (OGTT) stratified by a threshold fasting glucose level. In one study, OGTTs were performed in almost 1500 kidney transplant recipients, with specificity and sensitivity of FPG for the diagnosis of PTDM analysed [17]. The authors found an “optimal” threshold for performing an OGTT at a FPG value of 5.3 mmol/L (96 mg/dL). Using a lower FPG threshold of 5.0 mmol/L (90 mg/dL) would still not detect all PTDM patients (91%) but nearly two-thirds of patients would have to undergo an OGTT. These data also indicate that approximately 10% of patients with FPG of 5.0 mmol/L (90 mg/dL) and below may still be diagnosed with PTDM on the basis of an OGTT. These data were confirmed by a study by Bergrem and colleagues, which found only 20% of all kidney transplant recipients with PTDM would have been diagnosed based upon FPG glucose alone [19]. The authors of this study recommend an even lower FPG threshold for the

performance of OGTT; in their cohort a FPG threshold of 5.1 mmol/L (92 mg/dL) would identify 90% PTDM patients and require undertaking an OGTT in 50% of all patients at risk. There is no clear recommendation for the performance of OGTT in patients with a FPG ≥ 7.0 mmol/L (126 mg/dL) since this finding alone suffices for the diagnosis of PTDM. As holds true for many laboratory tests – pathologic glucose measurements should be repeated and no treatment decisions should be based on a single measurement [20].

During the first 4-6 weeks after transplantation, especially in centres using high corticosteroid doses usually administered in the morning, FPG alone is of even lower value in detecting hyperglycaemia since these patients typically experience post-prandial hyperglycaemic peaks in the afternoon [7,21]. Despite these limitations of FPG, it is acknowledged that patients with high values have poorer outcomes regarding graft and patient survival [22], and it remains a simple and generally effective screening test.

4.6 2-h plasma glucose during oral glucose tolerance testing

Performance of an OGTT (75 g of anhydrous glucose dissolved in water) is now widely accepted as the gold standard for diagnosis of PTDM and remains the diagnostic test of choice in the recent consensus guidelines due to a number of factors [4]. As previously highlighted, an OGTT will detect more patients with PTDM than measurement of FPG alone. In addition, it offers the possibility of detecting IGT, a pre-diabetes condition defined by a 2-hour plasma glucose (2hPG) between 7.8-11.0 mmol/L (140-199 mg/dL). IGT is pathophysiologically distinct from IFG and potentially has different therapeutic, as well as prognostic, implications in the general population as well as post-transplantation [64, 68, 69]. It is characterised by peripheral (muscle) insulin resistance and defects in early- and late-phase insulin response. In kidney transplant recipients the presence of IGT has been identified as an independent predictor of mortality, with each 1 mmol/L increment in 2hPG leading to a 5% increase in risk of all-cause mortality and a 6% increase in risk of cardiovascular-related mortality [6]. However, IGT has been shown to be positively influenced by life-style interventions in the general population and IFG appears to be less likely improved by such interventions [23,24]. Similar positive effects of lifestyle and pharmacological interventions on IGT have also been shown in kidney transplant recipients [25,26].

The disadvantages of OGTT include poor reproducibility and a relatively high time expenditure which makes its routine application for every kidney transplant unrealistic. The logistical obstacles for large and expanding prevalent SOT cohorts under hospital care follow up to prospectively use routine OGTTs for diagnostic purposes is challenging. The advantages of an OGTT should be reserved for specific situations, possibly stratified by other screening mechanisms such as combined risk factors or threshold FPG levels, to identify at-risk SOT recipients where diagnostic clarification of PTDM is essential.

4.7 Glycated haemoglobin (HbA_{1c})

For the diagnosis of diabetes, measurement of HbA_{1c} has a number of advantages compared to FPG or 2hPG. These advantages include standardised methods for quantification, better index of overall glycaemic exposure, less biologic variability, less pre-analytic instability, no need for fasting or timed samples, widely accepted use and minimal influence due to acute perturbations in glucose levels [27]. These advantages led to the decision to adopt HbA_{1c} as diagnostic marker for DM by the ADA and WHO in 2009 [11]. The utility of HbA_{1c} in the diagnosis of PTDM has been matter of debate, with the majority of published literature focused on kidney transplant recipients. HbA_{1c} is formed by a non-enzymatic posttranslational glycation in a two-step reaction via an aldimine to form the ketoamine HbA_{1c} in the presence of glucose [28]. The rate of glycation depends on temperature, pH, haemoglobin concentration, concentration of glucose and duration of glucose exposure. In patients with impaired kidney function the elevated urea levels lead to the generation of cyanate leading to the formation of carbamylated haemoglobin [29]. High levels of carbamylated haemoglobin interfere with the measurement of HbA_{1c} leading to falsely high HbA_{1c} levels only when charge-dependent HbA_{1c} assays are used, but not with standardised HPLC-based methods. Other factors that can lead to falsely elevated HbA_{1c} levels are acidosis [30], and iron deficiency [31]. There are also several factors that can artificially decrease HbA_{1c} levels, including blood loss, blood cell transfusions, shortened erythrocyte survival time and erythropoietin treatment - factors that commonly occur in patients after kidney transplantation [32]. During the first year after kidney transplantation approximately 50% of patients may still be anaemic, potentially leading to falsely lowered HbA_{1c} levels [33].

Prospective long-term data using HbA_{1c} as diagnostic tool for PTDM with analysis of macro- and microvascular complications are lacking, but there are several smaller studies explore

the accuracy of HbA_{1c} testing after kidney transplantation. Hoban and colleagues analysed 199 kidney transplant recipients, comparing FPG levels and HbA_{1c}, and demonstrated 14/20 patients with an elevated HbA_{1c} had FPG in the normal range [34]. HbA_{1c} may therefore be more sensitive than FPG, especially in African Americans, although no OGTTs were performed in this study to verify the diagnosis of PTDM. In a study by Shabir and colleagues, HbA_{1c} levels were compared in non-diabetic kidney transplant recipients with OGTT results at 3- and 12-months after transplantation [35]. The study demonstrated an HbA_{1c} value $\geq 6.5\%$ was associated with an 88.9% concordance for a positive OGTT-derived PTDM diagnosis at 3- and 12-months after transplantation. Conversely, a normal OGTT had a 98.7% concordance for an HbA_{1c} $< 6.5\%$. A further study tried to determine the optimal HbA_{1c} level at which an OGTT should be performed in order to detect PTDM [17]. The authors found that an HbA_{1c} cut-off value of 5.8% (40mmol/mol) had a sensitivity of 83% for the detection of PTDM and would help to reduce the need for OGTT transplant recipients. However, HbA_{1c} testing seems to be of little value in the early postoperative phase (0-3 months), because HbA_{1c} levels tend to be falsely lowered and only OGTT or afternoon glucose measurements should be performed for the detection of PTDM [36]. However, HbA_{1c} has been shown to be very predictive of risk of pre-diabetes and PTDM at 1- and 3-years after kidney transplantation in a single-centre study [37], although in a recent meta-analysis of six studies (n=2,057 kidney transplant recipients), early use of HbA_{1c} was shown to be highly specific but low/moderately sensitive to diagnose PTDM [38]. While supporting the use of alternative diagnostic tools in the early period after transplantation, at 1-year post renal transplantation, a combination of FPG and HbA_{1c} has been shown to be as good as an OGTT to capture persistent PTDM [39].

Taken together, it would appear HbA_{1c} measurements can be used in stable kidney transplant recipients for the detection of transplant associated hyperglycaemia and PTDM but not during the first three months after transplantation. While certain caveats in comparison to OGTT exist, its ease of use from a logistical perspective makes it an attractive diagnostic tool for detection of PTDM.

4.8 Continuous glucose monitoring (CGM)

CGM devices have now become widely available and its use has brought improvements in the management of type 1 diabetes (T1D) for distinct groups of patients, especially in

combination with continuous subcutaneous insulin infusions (CSII), and for hypoglycaemia unawareness [40]. Besides these clinical advantages, CGM offers the unique possibility to obtain continuous glucose profiles over days and weeks enabling clinicians to calculate glycaemic indices that could otherwise not be obtained [41]. These indices can help to describe glycaemic variability (GV) and control – parameters that are crucial for the pathophysiological understanding of DM and its treatment and may even help to predict the risk of diabetes-related complications [42].

Since kidney transplant recipients represent a group of patients with distinct alterations in glucose metabolism, for the most part due to the influences of immunosuppressive therapy, CGM technology holds promise in helping to gain a deeper understanding of PTDM. For example, it has been recently observed using CGM monitoring that patients with T2D show a higher GV than patients with PTDM [43]. Yates and colleagues have demonstrated, using CGM monitoring that divided dosing of prednisone reduce GV in kidney transplant recipients [44]. Two studies, one in children and one in adults, described the usefulness of CGM in kidney transplant recipients to detect hyperglycaemic episodes that would have remained undetected by routine laboratory testing [45,46]. Wojtusciszyn and colleagues showed in non-diabetic patients immediately after kidney transplantation that mean glucose levels determined by CGM are elevated in nearly every patient and that the degree of hyperglycaemia in this early phase might help identify patients at risk for later development of PTDM and graft failure [47]. CGM is therefore highly useful in the detection of early postoperative hyperglycaemia because FPG is often normal in these patients, HbA_{1c} is not reliable during the first three months after transplantation and OGTT is impractical in post-operative patients on the ward.

4.9 Fructosamine and glycated albumin

Fructosamine and glycated albumin are alternative measures for long term glycaemia but their linkage to average glucose and their prognostic significance are less clear when compared to HbA_{1c}. Glucose binds to serum proteins in a non-enzymatic reaction in proportion to its serum concentration by a process called glycation leading to the generation of glycated proteins. The term *fructosamine* refers to the sum of all ketoamine linkages between circulating glucose and serum proteins. These compounds do not contain fructose as the name is suggesting, but the resulting chemical product resembles the open-chain

form of fructose (this implies that all glycated proteins in the blood are fructosamines) [48]. Therefore, the main portion of fructosamine in the blood is glycated albumin since this is the most abundant serum protein. The half-life of serum albumin is 2-3 weeks and fructosamine therefore correlates with glycaemic control during the previous 1-3 weeks and can be seen as medium-term marker for glycaemia [49]. Determination of fructosamine as an index of diabetes control was introduced in the early 1980s [50], but has so far shown little benefit in the care of diabetes patients over blood glucose and HbA_{1c} monitoring [51]. Thus, fructosamine is usually only used in situations when no reliable HbA_{1c} measurements are possible, such as in patients with haemoglobinopathies or anaemia.

Considering the limitations of HbA_{1c} as a diagnostic tool in selected SOT recipients, there could be some rationale to determination of fructosamine or glycated albumin but this remains under study. There are limited publications on fructosamine or glycated albumin in the context of renal impairment for example. Morgan and colleagues found a good correlation between HbA_{1c} and mean blood glucose in patients on haemodialysis but the correlation between fructosamine and mean glucose was poor, probably due the shortened half-life of albumin in haemodialysis patients [52]. Another study compared the levels of fructosamine in healthy individuals to non-diabetic patients with chronic kidney disease (CKD), patients on haemodialysis, patients on peritoneal dialysis and finally patients after kidney transplantation; only kidney transplant recipients showed fructosamine levels similar to healthy controls [53]. One study found better correlations of glycated albumin and fructosamine with mean serum glucose as determined by CGM in CKD patients stage 4 and 5 (including dialysis patients) as compared to HbA_{1c} [54], whilst another demonstrated glycated albumin as a better indicator of glycaemia than HbA_{1c} in haemodialysis patients receiving erythropoietin therapy due to the above mentioned influences erythropoietin on HbA_{1c} levels [55]. However, many laboratories do not offer assays for glycated albumin and in light of the paucity of data and their contradictory results, the use of glycated albumin and fructosamine cannot be recommended for the diagnosis of PTDM at present. Larger studies evaluating their use in kidney transplant recipients are necessary to clarify this issue.

5.0 MANAGEMENT OF PTDM

5.1 Recommendations

1. Immediately post-transplant, early post-operative hyperglycaemia (glucose >11 mmol/L on two occasions within 24 hours) should be actively monitored and treated. If hyperglycaemia is mild (<14.0 mmol/L), oral hyperglycaemic therapy can be considered. Otherwise, early insulin therapy should be instituted either intravenously or subcutaneously (Grade 1C).
2. Glycaemic target for people with PTDM should be around 7% (53 mmol/mol), but adjusted according to degree of chronic kidney disease, age, co-morbidity, ability to self-manage, and patient preference (Grade 1B).
3. All people with a confirmed diagnosis of PTDM should be offered structured diabetes education (Grade 1B).
4. The diagnosis of PTDM must be conveyed to the patients' usual primary care practitioner, and the patient should be put on to a diabetes register (ideally coded as "post-transplant diabetes mellitus"), and offered structured diabetes care, along with regular screening for complications (Grade 1B).
5. If patients with a stable eGFR ≥ 30 mls/min/1.73m² and BMI ≥ 25 kg/m², metformin should be considered first line oral therapy for people with confirmed PTDM (Grade 1C).
6. Other therapies which may be used safely in PTDM include sulfonylureas, meglitinides, DPP-4 inhibitors, pioglitazone and GLP-1 analogues. Use of sulfonylureas and meglitinides should be undertaken with care especially in those at risk of hypoglycaemia, and doses should be adjusted according to eGFR (Grade 2C)
7. SGLT-2 inhibitors should be used with caution in patients with stable eGFR ≥ 30 mls/min/1.73m² and poor glycaemic control in patients at low risk of urinary tract infection, after careful discussion with nephrology and diabetes specialists (Grade 1C).
8. Insulin therapy should be considered in all patients who have inadequate glucose control, or who have symptomatic hyperglycaemia (Grade 1C).
9. Blood pressure should be controlled below 130/80 mmHg in all people with PTDM (Grade 1B).

10. All people with PTDM should be offered statin therapy, irrespective of cholesterol level (Grade 2D).
11. All people with PTDM should have access to specialist diabetes expertise within a multidisciplinary team setting (Grade 1C).

5.2 Areas for Future Research

1. What is the optimum management for in-patient hyperglycaemia in patients undergoing renal transplantation?
2. Is there a benefit of tight versus standard glucose control in the early or late post-transplant period?
3. Are low carbohydrate diets effective for management of PTDM?
4. What is the role of SGLT-2 inhibitors and GLP-1 analogues in the management of PTDM?
5. Does choice of immunosuppressive regimen influence onset and management of PTDM?

5.3 Audit recommendations

1. What proportion of patients with PTDM have good glycaemic control as determined by their individualised glycaemic target?
2. What proportion of patients with PTDM and stable eGFR above 30 mls/min/1.73m² are treated with metformin?
3. What proportion of patients with a diagnosis of PTDM are offered structured diabetes education, and have regular foot and eye screening?

5.4 Overview

Distinct categories of hyperglycaemia may be seen following SOT, including pre-existing diabetes (sometimes previously undetected), transient hyperglycaemia in the early post-operative period, and persistent PTDM [1]. Treatment of dysglycaemia post transplantation can be divided into treatment of acute hyperglycaemia in the early post-operative period, and longer-term treatment once renal function and immunosuppression is more stable (usually at around three months post-transplant).

5.5 Early post-operative hyperglycaemia and glucose management in hospital

Dysglycaemia in the early post-operative period following renal transplantation is common, and may be due to post-operative stress hyperglycaemia, high doses of corticosteroids used for immunosuppression, pain, infection or indeed previously undiagnosed diabetes exacerbated by the above [1]. In addition, β -cell function and insulin secretion appears to drop significantly post-transplant possibly related to immunosuppression [2].

The prevalence of dysglycaemia appears to be very high. In one study of 424 patients undergoing renal transplantation, 87% of patients not known to have diabetes prior to transplantation developed hyperglycaemia [3]. One Chinese study of liver transplant recipients showed a prevalence of new onset hyperglycaemia of 42.6% in 3339 patients undergoing liver transplantation [4]. In a further study using CGM sensors in 43 non-diabetic renal transplant recipients, hyperglycaemia was seen in all patients on day 1 post-transplant and in 43% of patients between day 1 and day 4 [5]. In-patient hyperglycaemia appears to be a good predictor of subsequent development of longer term PTDM. In a cohort of 377 patients undergoing renal transplantation, 30% of the cohort required hyperglycaemia treatment with insulin, and had a four-fold increased risk of PTDM compared to patients who did not require insulin [6]. Further studies have shown that in-patient hyperglycaemia is a potent risk factor for subsequent development of PTDM [7]. Early hyperglycaemia immediately post-operatively may also be a marker for acute rejection episodes [8] or chronic rejection [9], and peri-operative hyperglycaemia has been suggested as being associated with delayed graft function [10]. Day one post-operative hyperglycaemia has been suggested as a risk factor for increased risk of graft failure [11], although not in all

studies [12]. Post-operative stress hyperglycaemia is also noted to be a risk factor for mortality post liver transplantation [13].

Early post-operative insulin therapy following renal transplantation may have a role in preventing the subsequent development of PTDM. In a one-year proof of concept study, 50 renal transplant recipients were randomly assigned to immediate post-operative isophane insulin if evening glucose was $> 140\text{mg/dl}$ (7.8 mmol/L) compared to standard treatment of short acting or oral hypoglycaemic therapy if evening glucose was $180\text{-}250\text{mg/dl}$ ($10\text{-}14\text{ mmol/L}$) [14]. Early isophane therapy appeared to lead to a 73% risk reduction in the subsequent development of PTDM. The early isophane therapy group appeared to have better β -cell function at one year, suggesting that the isophane therapy may have offered some β -cell protection. The same group subsequently used continuous subcutaneous infusion of insulin (CSII) immediately post-operatively in 24 patients without diabetes, and found better glucose control than with isophane although subsequent outcomes for PTDM have yet to be reported [15]. Tight glycaemic control has been shown to reduce risk of post-operative infection in patients with liver transplantation [16].

Early post-operative hyperglycaemia post transplantation shares some similarities with steroid-induced diabetes. Corticosteroids typically induce hyperglycaemia by increasing resistance to insulin [17], and whilst the initial dose of steroids is high in the early post-transplant period, it is usually rapidly titrated downwards. Nevertheless, early post-operative hyperglycaemia post transplantation can have a significant steroid component. The Joint British Societies Guidelines on the Management of Hyperglycaemia and Steroid Therapy [18], offer consensus-based guidelines on glucose management in this scenario. They suggest the use of short-acting sulfonylurea may be considered, titrated to a maximum dose of 240mg in the morning and 80mg in the evening. If this is unsuccessful then treatment with a morning dose of isophane insulin is advocated.

Hyperglycaemia in the early post-operative period requires careful monitoring and management. Hyperglycaemic emergencies immediately following transplantation have been reported, and exclusion of diabetic ketoacidosis or hyperosmolar hyperglycaemic syndrome is important in such patients. A retrospective study of 39,628 renal transplant recipients and found that the incidence of DKA was $33.2/1,000$ individuals per year among

renal transplant recipients with DM and 1.9/1,000 individuals per year among recipients without DM [19].

Severe hyperglycaemia should be managed actively with variable rate intravenous insulin infusion (VRII), intravenous fluids and hourly blood glucose monitoring [20]. Specific glucose targets are not clear, but, as with many in-patient settings such as myocardial infarction or intensive care [21,22], there is no evidence for benefits of very tight glucose control in the in-patient post-transplant setting. Indeed one study suggests that a tight blood glucose target (70-100 mg/dl [3.9-5.5 mmol/L]) was associated with increased hypoglycaemia and future rejection episodes compared to a standard glucose target (70-180 mg/dl [3.9-10 mmol/L]) [23].

Once nutritional status is improved and the patient is stabilised, the patient should be converted from intravenous to subcutaneous insulin doses. There is strong evidence for one insulin regimen over another, and hence conversion to a once daily isophane insulin regimen (preferably given in the morning), with additional prandial insulin as needed, seems the most logical regimen.

5.6 Glycaemic targets in PTDM

Following the early post-operative period, the diagnosis of PTDM needs to be established (see section 2.0). Once established, the condition requires active monitoring and treatment.

There are a number of reports that suggest that PTDM has an adverse impact on patient survival, with some suggestion of a two-fold increase in mortality compared to people with normal glucose tolerance [24]. This increase in mortality largely attributable to increased cardiovascular mortality, although PTDM is also associated with increased risk of sepsis, [25], and CMV infection [26]. Similarly, many studies suggest a reduction in graft survival [24-27], although a potential source of bias is that rejection may lead to increased immunosuppression, and hence hyperglycaemia, rather than hyperglycaemia causing graft failure. A large retrospective study of people with PTDM has shown frequent microvascular complications of diabetes [28], suggesting that glucose control may be important in this respect. A more recent small Brazilian study, however, suggested that microvascular

complications were infrequent in PTDM [29]. Diabetic nephropathy has been described in subjects with PTDM [30].

Observational data suggests that glucose control may be important in patients with PTDM. In a Korean study of 3,538 kidney transplant recipients, 476 patients received kidney transplantation because of diabetic nephropathy [31]. Patients with diabetic nephropathy had poor graft and patient survival rates compared with non-diabetic nephropathy, and those patients with the highest quartile of time-averaged glucose had the worst graft outcomes. A study from Austria of 798 patients with renal transplants suggested that maximal glucose levels, but not HbA_{1c} was associated with poorer mortality in renal transplant recipients [32]. A retrospective study from the US, however, showed no benefit of improved glucose control on renal outcomes 12 months post renal transplant [33]. In a study of 210 lung transplant recipients, however, each 1% rise in HbA_{1c} was associated with a 48% increased risk in mortality [34].

There is currently no randomised trial evidence to suggest that better glucose control improves outcomes in people with PTDM. In the absence of such evidence, guidelines for targets used in T2D are probably appropriate for patients with PTDM, with the caveat that a number of therapies have not been tested in PTDM. In the UK, the National Institute for Health and Care Excellence (NICE), suggests an overall glucose target of around 7.0% (53 mmol/mol), but individualising glucose targets according to the persons' co-morbidity and risk of hypoglycaemia [35]. NICE states that clinicians should “adopt an individualised approach..... taking into account personal preferences, co-morbidities, risks from polypharmacy, and ability to benefit from long term interventions because of reduced life expectancy”, and that consideration should be given to “relaxing the target HbA_{1c} on a case by case basis, with particular consideration for people who are older or frail....., who are unlikely to achieve longer term risk reduction benefits, and for whom intensive management would not be appropriate, for example, people with significant co-morbidities”.

More recent guidance from the ADA and European Association for the Study of Diabetes (EASD) suggests an overall glucose target of 7.0% (53 mmol/mol), but similarly suggest that less stringent targets may be appropriate “for patients with a history of severe hypoglycemia, limited life expectancy, advanced microvascular or macrovascular complications, extensive comorbid conditions, or long-standing diabetes in whom the goal is

difficult to achieve despite diabetes self-management education, appropriate glucose monitoring, and effective doses of multiple glucose-lowering agents including insulin” [36].

Kidney Disease Improving Global Outcomes (KDIGO) recommends a glycaemic target of 7-7.5% (53-58 mmol/mol) due to high risk of hypoglycaemia and frequent history of cardiovascular disease in patients undergoing renal transplantation [37]. The ABCD-RA guidelines on managing hyperglycaemia in patients with diabetes and diabetic nephropathy-chronic kidney disease (DN-CKD) suggest less stringent targets according to grade of CKD, which we feels should also apply to PTDM [38] (table 2).

Table 2. Glycaemic targets in patients with diabetes and DN-CKD


	Glycaemic target	Note
Type 1 diabetes	48–58 mmol/mol (6.5–7.5%)	Younger patients within 10 years’ duration of diabetes and variable microalbuminuria–CKD stage 2
	58–62 mmol/mol (7.5–7.8%)	The majority of patients with proteinuria and/or CKD stages 3–4
	58–68 mmol/mol (7.5–8.5%)	Patients with CKD stage 5-dialysis
Type 2 diabetes	48–58 mmol/mol (6.5–7.5%)	For the majority of patients who are aged <40 years, or have CKD stages 1–2 (no basis to aim for <52 mmol/mol (6.9%) unless the patient is aged <40 years and has CKD stages 1–2)
	52–58 mmol/mol (6.9–7.5%)	For those with CKD stages 3–4 this target may be appropriate with a GLP-1–SGLT-2 inhibitor-based treatment regime without insulin
	58–68 mmol/mol (7.5–8.5 %)	For those with CKD stages 3–4-proteinuria who are on an insulin-based regime, and those with CKD stage 5 who are on dialysis

5.7 Glucose lowering therapies in PTDM

As the therapeutic armamentarium for management of hyperglycaemia increases, a number of newer therapies are now available to manage glucose in PTDM. This section aims to review the evidence behind each therapy and offer recommendations for their use. Figure 1 suggests a flow chart for the glycaemic management of PTDM.

One consideration when prescribing anti-diabetic therapy to patients with PTDM is the potential for interactions between immunosuppressants and anti-diabetic agents, which is well reviewed by Vanhove and colleagues [39]. For example ciclosporin inhibits cytochrome P450 3A4 enzyme, and may increase levels of prandial glucose regulators, gliptins, sulfonylureas and possibly sodium-glucose transporter-2 (SGLT-2) inhibitors. Although CNIs and mammalian target of rapamycin inhibitors (mTORi) are frequently prone to drug interactions, only glibenclamide and canagliflozin are likely to influence their levels significantly.

Figure 1. Flow chart for the glycaemic management of post transplant diabetes mellitus (PTDM)



5.7.1 Diet and lifestyle-based management

Weight gain following transplantation is common. The reason for this is multi-factorial, and includes being allowed a less restrictive diet after transplantation, improved appetite off dialysis, corticosteroid use and inadequate lifestyle changes [40]. There is some suggestion that females are at higher risk of weight gain than males post-transplant [41]. Mean weight gain in some studies is around 4-8 kg [42, 43]. Dietary intervention may reduce weight gain post-transplantation, but it has been suggested that nutritional care for patients undergoing renal transplantation is frequently neglected [44]. In one study of 33 patients randomised to intensive versus standard dietary intervention, weight gain in the intensive group was limited to 5.5 kg, whilst the standard group gained 11.8 kg [45].

Higher weight pre-transplantation is a risk factor for the development of PTDM, and is a target for prevention (see later) [46]. A clinical trial of dietitian delivered active versus passive lifestyle intervention in 130 renal transplant recipients has shown a reduction in development of PTDM, but the difference did not reach significance (7.6% versus 15.6% respectively, $p=0.123$) [47]. There was, however, a reduction in fat mass (mean difference -1.537kg [-2.947 to -0.127], $p=0.033$) and weight (mean difference -2.47kg [-4.01 to -0.92], $p=0.002$), but glycaemic indices did not change. Further trials of use of high protein and low glycaemic index diets [48], and other dietary interventions are ongoing [49]. A recently published prospective study of 468 renal transplant recipients showed that a Mediterranean Style Diet was associated with a lower PTDM risk [50].

In patients at risk for the development of diabetes, lifestyle intervention is proven to be of benefit for the prevention of diabetes [51,52]. There is currently no strong evidence that diet or lifestyle based will prevent or improve PTDM. Nevertheless, as diet and lifestyle change are the cornerstones of diabetes therapy in the non-transplant setting, high priority should be given to dietary intervention to manage hyperglycaemia and minimise weight gain in patients with PTDM.

5.7.2 Oral hypoglycaemics

5.7.2.1 Metformin

Metformin is contra-indicated in severe CKD with $\text{eGFR} \leq 30 \text{mls/min/1.73m}^2$. In the post-transplant setting, however, there is an opportunity to consider using metformin in patients with pre-transplant diabetes and PTDM if renal function allows. Metformin, however, does not appear to be widely used. In a large US survey of 14144 renal transplant recipients with pre-transplant diabetes, only 4.7% of them received metformin in the first 12 months post-transplant. Subjects on metformin had a significantly lower all cause, malignancy related and infection related mortality [53]. In a further US based observational study of 46914 transplant recipients, just under 10% of these patients received metformin, and unsurprisingly they had low creatinine values, but also better transplant survival and lower mortality [54]. One small retrospective study had shown no significant adverse effects with an average of 16 months of metformin therapy post renal transplant [55]. Metformin has been recommended by some as a potential first line agent for the treatment of hyperglycaemia in PTDM, due to its low cost, efficacy, and potential anti-obesity, anti-inflammatory and anti-neoplastic effects [56].

Metformin is first line therapy for treatment of T2D in many international guidelines. Whilst there is no strong evidence for its use in the post-transplant setting, in patients with stable renal function and no other contraindications, metformin therapy should be encouraged particularly in overweight patients with PTDM. The ABCD/RA guidance on managing hyperglycaemia in DN-CKD suggest the use of metformin “sick day rules” whereby metformin therapy should be temporarily stopped if a person becomes acutely unwell, but restarted if possible on recovery [57].

5.7.2.2 Sulfonylureas / Meglitinides

Due to their rapid efficacy and ease of administration, sulfonylureas are used commonly in patients with PTDM, although there is no available safety data for their use [58]. Nevertheless, they may be useful in the early post-transplant period for mitigating the hyperglycaemia induced by corticosteroids (see above).

In a small observational study of 23 patients with post-transplant diabetes, repaglinide, a short acting prandial glucose regulator, was used to treatment hyperglycaemia. Mean HbA_{1c} dropped from 7.6% to 5.8% in 14 patients, whilst the remaining nine subjects required progression to insulin therapy [59].

Whilst sulfonylureas and prandial glucose regulators may be useful in the early post-transplant period, their use must be balanced with the risk of hypoglycaemia, particularly when immunosuppressive regimes are being titrated downwards. Patients should be carefully counselled about this risk, and should undertake regular self-monitoring of glucose (SMBG).

5.7.2.3 Glitazones

Glitazones are safe and effective in patients with renal disease, and have been used in small studies of patients with PTDM. In one study of 10 patients treated with insulin or glyburide post-transplant, the addition of pioglitazone lowered HbA_{1c} by around 1.4% (12 mmol/mol) and reduced dose of insulin [60]. A study of non-diabetic renal transplant recipients randomised to pioglitazone or placebo showed a modest benefit in carotid intima-media thickening [61]. Small studies of rosiglitazone (no longer available in Europe) have also been published, suggesting moderate efficacy [62,63]. In one study of 40 patients with PTDM initially stabilised with insulin, all were converted to rosiglitazone at 3-4 months post-transplant and only three out of 40 required insulin subsequently [64]. Glitazones may be useful to treat liver steatosis in post liver transplant patients [65]. Adverse effects of fluid retention, weight gain and increased fracture risk limit the use of these drugs in patients with T2D, especially amongst those with renal disease.

5.7.2.4 Dipeptidylpeptidase-4 (DPP-4) inhibitors (gliptins)

By virtue of their lack of side effects and ease of administration, gliptins are now widely used for the management of T2D. In animal models of PTDM, gliptins appear to have beneficial effects on sirolimus induced oxidative stress [66]. There are some studies of their use in the setting of PTDM, but all are small, short term and non-controlled. In a retrospective study of 22 patients with PTDM treated with sitagliptin, 17 patients achieved good glycaemic control (HbA_{1c} <7.0%) [67]. In a prospective randomised cross over study of 19 patients with PTDM, sitagliptin 50-100mg was crossed over with a sitagliptin free period of four weeks [68]. Sitagliptin improved first and second phase insulin responses, fasting and post-prandial glucose levels.

Sitagliptin has also been used in a single centre pilot study of 15 patients with PTDM, and found an HbA_{1c} reduction of 0.5%, and no effect on sirolimus or tacrolimus levels [69]. A further retrospective study from India of 21 patients with PTDM treated with linagliptin found a decrease in HbA_{1c} by an average of 0.6% (6mmol/mol) over 24 weeks treatment [70]. A randomised trial of 32 patients with PTDM treated with vildagliptin or placebo showed a significant reduction in 2-hour plasma glucose and HbA_{1c} (by 0.4% {4 mmol/mol}) [71]. In a Korean study of 65 renal allograft patients with PTDM, comparison of the efficacy of linagliptin, sitagliptin and vildagliptin was undertaken, and showed that linagliptin appears to be more efficacious in reducing HbA_{1c} compared to other gliptins (mean reduction of 1.4% (12 mmol/mol) in linagliptin treated patients) [72]. When compared to the addition of insulin glargine to 17 patients with PTDM, the addition of sitagliptin to 28 patients inadequately controlled PTDM led to similar reductions in HbA_{1c} (0.6% {5 mmol/mol}), but with a 1.2 kg difference in weight change between the two agents [73]. A further study of 14 patients treated with linagliptin plus insulin versus insulin treated alone patients with post-transplant hyperglycaemia suggested that glucose control was better and insulin dose and hypoglycaemia was lower in the linagliptin plus insulin treated group [74].

Vildagliptin has also been used in cardiac transplantation. In a study of 30 cardiac transplant patients with PTDM, 15 of who were treated with vildagliptin, and 15 of whom were not, showed a reduction in HbA_{1c} of 0.6% {5 mmol/mol} [75]. Vildagliptin has also been used in post-transplant impaired glucose tolerance (IGT) [76]. In this study of 48 patients were randomised to pioglitazone, vildagliptin or placebo for three months. Two-hour plasma glucose fell in both groups significantly compared to placebo.

A systematic review and meta-analysis of five studies of gliptins in patients with PTDM suggested these drugs were effective in the post-transplant setting, leading to an average HbA_{1c} reduction of 0.993% (10 mmol/mol), with no change in eGFR or tacrolimus levels [77].

5.7.2.5 Glucagon-like Peptide-1 (GLP-1) analogues

GLP-1 analogues are increasingly used in patients with CKD, with a number of agents licenced for use down to eGFRs of 15ml/min/1.73m² [78]. They have the advantage of improving glucose control, with the addition of weight loss, which is useful in the post-transplant setting at outlined previously. There is very little data about the use of GLP-1 in

the post-transplant setting, but small case series do suggest they may be effective. PTDM is characterized by reduced glucose-induced insulin secretion and reduced glucagon suppression during hyperglycaemic clamp, and studies of patients with PTDM using a GLP-1 infusion appears to improve these insulin and glucagon defects [79]. A case series of liraglutide used in five patients with PTDM resulted in significant reductions in fasting and two hour glucose levels and body weight, and did not results in changes in tacrolimus levels [80]. A further small retrospective case series of seven Taiwanese transplant patients saw a 1.9% (20 mmol/mol) reduction in HbA_{1c} and 2.9 kg weight loss over a mean of 19.4 months of follow up [81].

The largest cohort of GLP-1 analogues in PTDM so far reported is a single centre retrospective chart review of 63 patients with solid organ transplants treated with the GLP-1 analogue, dulaglutide [82]. 49 patients had at least 12 months follow up, and mean weight reduction of 4kg was seen, with HbA_{1c} reduction of 0.4% (4 mmol/mol), and insulin dose reduction of a mean of around six units.

5.7.2.6 Sodium Glucose Transporter-2 (SGLT-2) inhibitors

There is increasing evidence that SGLT-2 inhibitors are cardio- and renoprotective [83]. Empagliflozin and canagliflozin have shown impressive benefits in patients with CKD, in particular in reducing progression to ESRD, doubling of serum creatinine and renal mortality. In the setting of PTDM, the potential side effect of genito-urinary infection is a concern [84,85], and rarely diabetic ketoacidosis (DKA) may complicate therapy with these drugs [86]. Currently only a few studies have reported on the use of SGLT-2 inhibitors in renal transplantation [87]. In one study, 14 patients with PTDM treated with insulin were converted to oral empagliflozin 10mg daily, of whom, two dropped out due to inadequate glucose control, two developed urinary tract infection, and two dropped out due to worsening renal function. Of the eight remaining patients, three required reinstitution of insulin therapy, and the other five remained stable on empagliflozin.

In a larger placebo controlled study of 44 renal transplant recipients, a very modest reduction in HbA_{1c} of 0.2% (2 mmol/mol) was seen, although this was significantly greater than placebo [88]. Body weight reduced by 2.5 kg. The magnitude of HbA_{1c} reduction was, however, dependent on baseline HbA_{1c} and eGFR. There were no significant differences in adverse events.

A recent pilot study of canagliflozin in 24 renal transplant patients in India showed a mean 0.9% reduction in HbA_{1c} in patients treated with the drug, along with a mean 2.5 kg weight loss, with no significant adverse effects or change in serum creatinine [89].

5.7.2.7 Insulin

Insulin therapy is frequently required in PTDM, particularly in the early post-transplant period where acute hyperglycaemia following surgery, exacerbated by high dose immunosuppression and potentially infection. Once transplant function is more stable, however, and immunosuppression is reduced, there may be an opportunity to reduce or even stop insulin therapy.

There is no randomised study of insulin regimens in PTDM. As early post-operative hyperglycaemia may be managed with once daily NPH insulin, this seems the regimen of choice for most patients, particularly as it may usefully reduce post prandial hyperglycaemia which is typical of steroid induced hyperglycaemia. As steroid doses are weaned, insulin doses may be able to be titrated downwards. Longer term, however, insulin therapy may be required in PTDM, and standard regimens such as basal insulin, twice daily fixed mixtures or basal bolus regimens may be required.

5.8 Management of cardiovascular risk factors in people with PTDM

Despite screening for cardiovascular disease in all patients prior to transplantation, cardiovascular disease is a significant problem amongst patients undergoing SOT [90]. The addition of PTDM appears to add significantly to this burden of cardiovascular disease, and therefore cardiovascular risk reduction is mandatory. Traditional cardiovascular risk factors are not very predictive of cardiac events in renal allograft recipients [91].

Smoking cessation is mandatory, as there is a high risk of allograft failure in smokers compared to non-smokers [92], and smoking may increase the risk of PTDM [93].

Dyslipidaemia is common amongst patients undergoing transplantation, which may be related to immunosuppression and other factors [94]. The Assessment of LEscol in Renal Transplantation (ALERT) study randomised over 2100 low risk renal transplant recipients to fluvastatin or placebo, and despite a 32% reduction in LDL cholesterol, no significant difference in major adverse cardiovascular events (MACE) was seen [95]. A Cochrane meta-analysis of 17 studies of statin use in renal transplant recipients showed non-significant reductions in MACE (RR 0.84, 95% CI 0.66–1.06), cardiovascular death (RR 0.68, 95% CI 0.45–1.01), and myocardial infarction (MI - RR 0.70, 95% CI 0.48–1.01). Nevertheless, KDIGO guidelines suggest statin therapy for all renal transplant recipients [37], aiming for a target LDL cholesterol below 100mg/dl (2.6mmol/L). There is little data on the use of non-statin medications in the post-transplant setting.

Hypertension is common post transplantation, and if uncontrolled, is associated with adverse graft outcomes. Angiotensin converting enzyme inhibition (ACEI) or angiotensin receptor blockade (ARB) may be drugs of first choice in patients with stable renal function, but there is no strong evidence for benefit in graft survival or reduction in mortality [96]. Additionally, there is currently no strong evidence for the optimum blood pressure target for renal transplant recipients. The KDIGO guidelines suggest a target blood pressure of 130/80 mmHg for patients with renal allografts [37], which concurs with the blood pressure target of 130/80 mmHg in patients with diabetic renal disease and hypertension [97].

5.9 Structured diabetes care and screening for diabetes complications

All patients with diabetes should undergo annual checks for diabetes related complications in a structured way. In the UK, many patients with diabetes do not undergo their eight key processes of care (eye check, foot check, HbA_{1c}, cholesterol, creatinine, albumin creatinine ratio, body mass index, smoking status) each year, and this may be exacerbated in patients with PTDM, in whom the responsibility for delivering these key processes may not be clear, particularly as many of these patients are attending specialist transplant clinics on a frequent basis. There is conflicting data about microvascular complications of diabetes in PTDM. One survey of 21,489 US renal data system patients with renal transplants suggested

a lower rate of microvascular complications compared to patients with T2D, but in those who did develop complications, their progression appeared to be accelerated [29]. Therefore microvascular complications need careful and regular surveillance.

All patients with PTDM should be registered in a primary care diabetes register, and receive standard call and recall for screening and management within primary care. Close liaison with the transplant team, however, will be required, especially when additional therapy for glucose or cardiovascular risk factors is warranted.

In large transplant centres, there may be a benefit in having all patients with PTDM managed in a multi-disciplinary clinic involving diabetes and renal specialist nurses, doctors, pharmacists and dietitians.

6.0 MODIFICATION OF IMMUNOSUPPRESSION TO PREVENT OR TREAT PTDM

6.1 Recommendations

1. Whilst immunosuppression is a major risk factor for PTDM, any planned modification to attenuate this risk should be balanced against the risk for allograft rejection (Grade 1B).
2. Individualisation of immunosuppression based on the recipient's immunologic and glycaemic risk must be taken as part of an overall strategy to improve long term transplant outcome (Grade 1C).
3. Until further evidence emerges, we adopt the recommendation that the choice of immunosuppressive therapy should be primarily to prevent rejection rather than preventing PTDM (Grade 1C).
4. There is no evidence to suggest changing immunosuppressive therapy when hyperglycaemia is detected has a role in the management of PTDM (Grade 2B).
5. There is as yet no evidence that newer agents such as belatacept are beneficial in reducing risk of PTDM compared to tacrolimus-based regimens (Grade 1C).

6.2 Areas for Future Research

1. PTDM should be included as a clinical endpoint in randomised controlled trials of new immunosuppressive agents.
2. How do the competing risks of PTDM and rejection compare as risk factors for adverse long-term clinical outcomes?
3. Is there any glycaemic benefit from prolonged-release versus immediate-release tacrolimus formulations?
4. In low immunological risk patients at high risk for PTDM, does a modified immunosuppression regimen (e.g. steroids sparing, CNI conversion) lead to improved short-term (e.g. PTDM, rejection) and long-term (graft function, cardiovascular events, graft loss, mortality) clinical outcomes?
5. Explore the risks and benefits of newer immunosuppressive agents as they enter clinical practice (e.g. PTDM versus other complications).

6.3 Audit recommendations

- 1. How many transplant units have stratified immunosuppression regimens for renal transplant candidates at increased risk for PTDM?**

6.4 Overview

Immunosuppressive therapy used in kidney transplantation can be categorised into induction which includes antithymocyte globulin (ATG), basiliximab and alemtuzimab, or maintenance therapy which includes corticosteroids, CNIs - tacrolimus and ciclosporin, azathioprine, mycophenolate mofetil (MMF), mTORi - sirolimus and everolimus, and belatacept. The action of immunosuppressive therapy is to prevent acute rejection and maintain long term transplant function. Steroids, CNIs and mTORi are associated with an increased risk of PTDM.

Immunosuppressive therapy predominates all known transplant specific risk factors for the development of PTDM which is associated with increased cardiovascular risk [1] transplant dysfunction [2] and increased cost [3].

Whilst early guidelines from the International Expert Panel in 2003 [4], KDIGO 2009 [5] and the Renal Association (RA) endorsed by the British Transplant Society (BTS) in 2010 [6], advocate modifying or switching immunosuppression is necessary to prevent or minimise the risk of development of PTDM, subsequent International Consensus Meeting guidelines in 2013 [7], and the RA endorsed by BTS in 2017 [8], advocate that the choice of immunosuppressive therapy should be to primarily prevent rejection rather than preventing PTDM. These conflicting opinions exist as data from large RCTs with long term follow up on the effect of modifications in the immunosuppressive regimens on PTDM are limited. It is notable that most transplant units in the UK follow their own local protocols for immunosuppressive regimens, with no uniform national guidance available.

6.5 Corticosteroids

There is intense debate on risk versus benefit of corticosteroid sparing for the development of PTDM. Two RCTs showed no clear benefits of steroid sparing regimens on decreasing the incidence of PTDM. The first one reported in 2005 on the five year results of a multicentre RCT of early corticosteroid withdrawal (CSWD) versus chronic corticosteroids (CCS), MMF and tacrolimus in 386 kidney transplant recipients. At five years, the proportion of patients with PTDM requiring any therapy was similar between groups (CSWD [21.5%]; CCS [20.9%] [9]. The second study enrolled 277 patients, and showed no significant impact of early

steroids withdrawal compared with long term maintenance steroids of 5mg daily, tacrolimus and MMF on the incidence of PTDM in patients diagnosed with PTDM from six months to five years of kidney transplantation [10].

A Cochrane systematic review including 7800 renal transplant recipients published in 2017 confirmed no difference in the occurrence of PTDM between steroid withdrawal and steroid maintenance strategies up to five years post transplantation [11]. It did however show a significant increase in the risk of acute rejection (AR) with steroid withdrawal either earlier (by 58%) or later (by 77%) than 14 days post transplantation versus steroid maintenance, but no association with patient mortality or graft loss.

By contrast, a multicentre RCT including 538 patients followed up for six month post renal transplantation and showed a significantly reduced incidence of PTDM (5.4% vs. 0.4%, $p=0.003$) with steroid-free immunosuppression [12]. Similarly in a prospective controlled study of 300 renal transplant recipients with three years follow up, two day steroid withdrawal significantly reduced risk of PTDM without affecting the incidence of acute rejection, graft function or patient or graft survival [13].

Evidence from a meta-analysis published in 2010 showed steroids sparing benefits on PTDM risk was countered by an increased risk of rejection [14]. This meta-analysis included thirty-four studies of 5,637 patients and showed that steroid avoidance/withdrawal (SAW) regimens significantly increased the risk of acute rejection (AR) over maintenance steroids ($p<0.0001$) but significantly reduced new onset diabetes ($p=0.0006$). No significant differences in corticosteroid resistant acute rejection, patient survival, or graft survival were observed. Serum creatinine was increased and creatinine clearance was reduced with SAW. Data on the relationship between steroid-free maintenance regimens and PTDM in a cohort of 25,837 adult kidney transplant patients published in 2015 concluded that the adoption of steroid-free maintenance immunosuppression at discharge from kidney transplantation in selected patients was associated with reduced odds of developing PTDM within three years [15].

A subsequent meta-analysis in 2012 of 29 RCT included 5675 patients showed that steroid avoidance versus steroids maintenance was associated with less frequent PTDM requiring

any treatment, although this decrease was only evident with ciclosporin, not with Tacrolimus [16].

A more recent retrospective analysis with longer follow up of 15 years in 1553 patients post renal transplantation suggested that rapid discontinuation of steroids was associated with reduced onset of PTDM without decreasing patient or graft survival or increased graft dysfunction [17]. Two recent RCTs, Harmony (615 patients) and Advance (1081 patients) also showed evidence of reduction of incidence of PTDM with steroids-sparing regimens [18, 19].

It is possible that the discrepancy of findings of various studies on the effects of steroid withdrawal on the incidence of PTDM may be due to the increased diabetogenic effect of ciclosporin or tacrolimus thus reducing any potential benefits of steroids sparing regimens on reducing the incidence of PTDM. It is also possible that high trough level of CNIs is responsible for the absence of beneficial effects of steroids sparing on reducing the incidence of PTDM [20].

The findings of various studies suggest that steroids sparing regimens can be used as a mechanism to reduce risk of PTDM. Longer term data beyond five years is, however, lacking. Additional end points of potential benefits of steroid sparing regimens such as prolonging patient and graft survival will likely to be required to demonstrate efficacy of such regimens versus steroids based therapies.

6.6 Calcineurin inhibitors

CNIs have been associated with increased risk of PTDM with tacrolimus being more potent than ciclosporin in reducing insulin secretion in vitro and vivo [21]. A meta-analysis of 56 studies (including 16 RCTs) showed that risk of PTDM with tacrolimus was 16.6% compared to 9.8% in those received ciclosporin [22]. A further meta-analysis including data from 30 RCTs with 4102 patients, suggested that risk of PTDM was significantly increased in tacrolimus treated recipients at six months and three years [23]. A subsequent large observational study of 527 patients showed that the risk of PTDM at two years was significantly higher in a tacrolimus based regimen versus ciclosporin [21% vs 8%] [24].

The DIRECT RCT included 567 patients comparing tacrolimus and ciclosporin, with PTDM as the primary end point showed that the incidence of PTDM or IFG at six months post renal transplantation was significantly lower with ciclosporin (26%) than with tacrolimus (33.6%) [25].

A subsequent larger RCT reported on 638 patients with four years follow up and also showed the incidence of PTDM was significantly higher in tacrolimus treated patients [26]. A recent open-label, multicentre, RCT included 128 patients testing whether a tacrolimus-based immunosuppression and rapid steroid withdrawal (SW) within 1 week (Tac-SW) or ciclosporin with steroid minimization (SM) (CsA-SM), decreased the incidence of PTDM compared with tacrolimus with SM (Tac-SM). All arms received basiliximab and MMF. The 1-year incidence of PTDM in each arm was 37.8% for Tac-SW, 25.7% for Tac-SM, and 9.7% for CsA-SM. Antidiabetic therapy was required less commonly in the CsA-SM arm ($p = 0.06$), however the acute rejection rate was higher in CsA-SM arm (Tac-SW 11.4%, Tac-SM 4.8%, and CsA-SM 21.4% of patients; cumulative incidence $p=0.04$). Graft and patient survival, and graft function were similar. Although the authors concluded that in high-risk patients, tacrolimus-based immunosuppression with SM provides the best balance between PTDM and acute rejection incidence, they suggested that tacrolimus based regimen with SM may be used to prevent acute rejection during the early post-transplant period and to replace tacrolimus with ciclosporin in patients with inadequately controlled PTDM in the maintenance phase [27].

Based on the above studies, given the lower risk of PTDM with ciclosporin versus tacrolimus, conversion studies from tacrolimus to ciclosporin followed to assess risk reduction of PTDM. An RCT published recently included 80 patients with 12 months follow up and showed that 39% of patients in the ciclosporin arm were off glucose-lowering medication vs 13% of patients in the tacrolimus arm ($p=0.01$). The ciclosporin group, decreased HbA_{1c} levels were noted during the 12-month follow-up compared with the tacrolimus group ($p=0.002$). The risk of acute rejection was not increased, but ciclosporin conversion was associated with a reduction in renal function. The authors concluded that replacement of tacrolimus with ciclosporin significantly improved glucose metabolism and had the potential to reverse diabetes during the first year after conversion and reduced need for glucose-lowering therapy in a significant proportion of patients with PTDM after renal transplantation [28].

The authors subsequently conducted an economic evaluation to support NICE in developing updated guidance on the use of immunosuppression, and suggested that for patients at risk of diabetes or at risk of complications from diabetes, it may be more effective and cost effective to use ciclosporin, since diabetes is associated with adverse events and increased mortality [29]. However their conclusion was primarily that basiliximab, tacrolimus and MMF are likely to be optimal immunosuppressants (in terms of cost-effectiveness) for the majority of adult kidney transplant recipients in the NHS, and that ciclosporin offered the second-best net health benefit after immediate release-tacrolimus.

Based on the above studies, there are a number of advocates suggesting that modification of immunosuppressive therapy from tacrolimus to ciclosporin in those who develop hyperglycaemia post renal transplantation should be considered [4,5,6].

CNI sparing has emerged as a strategy to reduce risk of PTDM following a meta-analysis. The analysis included 56 RCT reporting on 11,337 renal transplant recipients and showed that CNI sparing regimens reduced the incidence of PTDM [30]. A more recent Cochrane meta-analysis review that included 83 studies and 16,156 renal transplant recipients was reported in 2017 [31]. This analysis sub classified CNI sparing studies into four different interventions groups and analysed them as CNI withdrawal or low dose CNI and standard regimens. They suggested, however, no improvement in PTDM rates using CNI sparing regimens.

6.7 mTOR inhibitors

Regimens enabling CNI reduction may be beneficial to reduce the long term unwanted effects of CNIs including risk of PTDM. Although mTORis may be diabetogenic, results from RCTs and meta-analyses have been published to assess its effects as maintenance immunosuppressive therapy post renal transplantation including its effect on the incidence of PTDM.

A meta-analysis published in 2006 included 33 trials reporting on 7114 renal transplant recipients and evaluated mTORi (everolimus and sirolimus) in four different primary immunosuppressive regimens and concluded that there is no differences in incidence of PTDM up to two years post renal transplantation [32].

However, analysis of the larger USRDS dataset reporting on 20,124 renal transplant recipients showed that combinations that included sirolimus, combined with a CNI or MMF or azathioprine were associated with higher risk of PTDM, with the most diabetogenic combination with CNIs [33]. In 16,681 patients who did not change therapy during the first year post renal transplantation, sirolimus was associated with increased risk of PTDM only in the presence of a CNI. A more recent meta-analysis on conversion from CNI to everolimus included 11 RCTs reporting on 1633 patients assessing the efficacy and safety of everolimus for maintenance immunosuppression. The one year follow up data showed lower incidence of PTDM although this was at increased risk of AR at one year [34].

Further data on mTORi and risk of PTDM has come from an RCT which included 613 renal transplant recipients randomised into everolimus plus low dose tacrolimus or MMF plus tacrolimus in de novo renal transplant recipients [35]. The results demonstrated that everolimus facilitates tacrolimus reduction while achieving good renal function and low acute rejection and graft loss rates, with incidence of hyperglycaemia at 12 months of 24.8% in the everolimus and low dose tacrolimus, versus 27% of standard tacrolimus and MMF. This suggests that the incidence of PTDM is not increased by the use mTORi in comparison to CNI.

6.8 Belatacept

A more contemporary approach to reduce risk of PTDM post renal transplantation is to use CNI sparingly with new agents such as belatacept. This is a parental immunosuppressant that replaces CNI and selectively inhibits T-cell activation through co stimulation blockade. In an RCT of 1209 patients randomised to belatacept based regimens versus ciclosporin based regimens, at one year, a lower incidence of PTDM was seen with belatacept [36]

In a meta-analysis of RCTs reporting on 1535 patients comparing betalcept against any other immunosuppression regimen with three years follow up showed patient survival, graft loss, and acute rejection were all similar, but that belatacept treated patients were 28% less likely to have chronic kidney scarring and better GFR than CNI treated recipients, and the risk of PTDM was reduced by 39% [37].

Subsequently, the BENEFIT study appeared to confirm these findings, showing a 43% reduction in the risk of death or graft loss for belatacept based regimens compared with ciclosporin regimen. In addition, mean eGFR was significantly higher and risk of death or graft loss after seven years was significantly lower for belatacept-treated patients [38]. There was no mention of risk of PTDM in this study.

Comparison of tacrolimus based regimens with belatacept has shown slightly differing results. In a retrospective cohort study using registry data on 50,244 patients, comparing one year clinical outcomes between belatacept- and tacrolimus-treated kidney transplant recipients, belatacept alone was associated with a higher risk of acute rejection, with the highest rates associated with non-lymphocyte-depleting induction [39]. There was no significant difference in rejection rates between belatacept plus tacrolimus and tacrolimus alone. The incidence of PTDM was significantly lower with belatacept plus tacrolimus and belatacept alone versus tacrolimus alone. Similar results were recently obtained from a small RCT in which 40 patients were randomised to belatacept vs tacrolimus in addition to MMF and Pred [40]. The risk of acute rejection was 55 % in the belatacept group vs 10% of the tacrolimus group - no data on risk of PTDM was provided.

6.9 Induction agents

A number of studies report on the impact of induction agents on the risk of PTDM. A single-centre retrospective study of 264 renal transplant recipients showed induction with IL-2RA basiliximab was associated with a significantly greater risk of developing PTDM compared to no induction (51.5%vs. 36.9%) at 10 weeks post transplantation [41]. This was also seen in a prospective observational study of 439 renal transplant recipients, where PTDM was observed in (16.7%) of patients without induction and (30.5%) of patients with basiliximab induction [42]. This may suggest that although basiliximab may reduce acute rejection, it appears to be associated with an increased risk of PTDM.

Meta-analysis of 10 RCTs of 1223 patients looking at induction regimens IL-2RAs, alemtuzumab and rabbit ATG suggests that these agents are not associated with increased risk of PTDM [43]. A further meta-analysis of 446 patients from six RCTs showed similar findings [44].

Table 3 below outlines the PTDM risk of commonly used immunosuppressive regimens.

Table 3. Risk of PTDM with commonly used immunosuppressive regimens

	Post-transplant diabetes mellitus risk
Corticosteroids	Increased
Tacrolimus	Increased
Cyclosporin	Slightly increased
mTORi	Slightly increased
Mycophenolate Mofetil	No effect
Azathioprine	No effect
Belatacept	Slightly decreased?
Basiliximab	Slightly increased?

7.0 PREVENTION OF PTDM

7.1 Recommendations

1. The risk for development of diabetes should be assessed as part of a pre-transplant work-up for all people being considered for transplantation (Grade 1B).
2. All people awaiting transplantation should be educated on the risk of developing PTDM, should be counselled about minimising weight gain using lifestyle measures, and should see a dietitian with expertise in this area (Grade 1B).
3. Treatment of risk factors for PTDM such as hepatitis C should be considered in patients awaiting transplantation (Grade 1C).
4. In people considered at high risk for the development of PTDM, consideration should be given to immunosuppressive therapy that is less prone to inducing hyperglycaemia but this should be based on individualised risk with immunological status in mind (Grade 1C).
5. All patients deemed at high risk for development of PTDM should be screened yearly for diabetes whilst awaiting transplantation (Grade 1B).

7.2 Areas for future research

1. What is the role of standard risk scores for predicting the development of PTDM?
2. Does intensive lifestyle intervention prevent the development of PTDM?
3. Is there a role for pharmacotherapy (metformin, GLP-1 analogues, orlistat) in the prevention of PTDM?

7.3 Audit recommendations

1. What proportion of patients awaiting transplantation are risk assessed for the development of PTDM?

7.4 Lifestyle intervention

Risk factors for the development of PTDM are similar to those of T2D and outlined in greater detail in section 4.0. Prevention or delay of T2D is feasible using lifestyle intervention [1-3] or pharmacotherapy [1,2,4-7]. More recently, remission of T2D has been achieved with very low calorie diets [8]. There are additional risk factors for PTDM that may be modifiable (for example type of immunosuppression, cytomegalovirus or hepatitis C infection) [9]. Risk scores for the development of T2D are well described (eg QDiabetes) [10]. Chakkerla and colleagues suggest a pre-transplant risk score comprising seven variables of older age, planned corticosteroid therapy after transplant, prescription for gout medicine, higher BMI, higher fasting glucose, higher triglycerides, and family history of T2D could predict most cases of PTDM [11]. Other risk scores also evaluated in PTDM include the San Antonio Diabetes Prediction Model and the Framingham Offspring Study-Diabetes Mellitus algorithm [12].

As described in section 6.0, weight gain following transplantation is common, often due to fewer dietary restrictions after transplantation, improved appetite off dialysis, corticosteroid use and inadequate lifestyle changes [13]. Nutritional care for patients undergoing renal transplantation is advocated by KDIGO guidelines, but frequently not given high priority [14]. Dietary intervention may reduce weight gain post-transplantation [15]. Higher weight pre-transplantation is a risk factor for the development of PTDM, and is a target for prevention [16]. Clinical trials of active versus passive lifestyle intervention in renal transplant recipients are underway [17-19]. Mediterranean Style Diet may be associated with a lower post-transplant diabetes risk [20]. Increased vegetable intake, but not fruit intake, has been associated with reduced risk for PTDM likely due to beneficial effects on components of the metabolic syndrome [21]. The effect of lifestyle modification on PTDM has been tested in a small study and may have an important beneficial effect. Amongst 115 renal transplant recipients, a group with IGT / PTDM were treated with lifestyle modification and exercise advice for six months. 44% of the IGT group went on to have normal glucose tolerance, and 4% developed PTDM. Overall there was a modest reduction (15%) in post prandial glucose excursion in the whole group [22]. A larger study of 130 patients undergoing renal transplantation randomised to active versus passive lifestyle intervention is currently recruiting [17].

There is currently no strong evidence that diet or lifestyle based will prevent or delay PTDM. Nevertheless, as diet and lifestyle change are the cornerstones of diabetes therapy in the non-transplant setting, high priority should be given to dietary intervention to manage hyperglycaemia and weight gain in patients with PTDM.

Bariatric surgery has a potent effect on prevention (or indeed remission) of T2D in high risk patients [23]. In patients in haemodialysis, there may be a role for bariatric surgery to prevent development of diabetes [24,25]. In one series of 24 patients undergoing bariatric surgery whilst on dialysis, pre-operative BMI mean was 41 kg/m², and dropped to a mean of 28 kg/m², facilitating transplantation in 16 patients subsequently [24].

7.5 Pharmacological intervention

In the non-transplant setting, a number of pharmacological agents have been shown to prevent or delay the onset of T2D in individuals at high risk (for example in people with impaired glucose tolerance ((IGT)). Agents used in this circumstance include metformin [1,2,4], rosiglitazone [5], pioglitazone [6], acarbose [7], orlistat [26] and liraglutide [27].

In renal transplantation, there are a small number of studies involving small numbers of patients with pharmacotherapy aimed at preventing the onset of PTDM. A study of 48 patients with stable renal transplants and IGT treated with three months of vildagliptin or pioglitazone led to a significant reduction in two hour glucose concentration [28], but no mention of prevention of PTDM is made. A larger study of sitagliptin to prevent PTDM is currently actively recruiting [29]. One study of metformin in patients with PTDM and impaired glucose tolerance has recruited 19 patients and is awaiting results [30]. Finally, the PRODIG study (*Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period*) is a planned French multi-centre RCT exploring the benefit of short-term (two months) vildagliptin in non-diabetic renal transplant recipients to prevent the onset of PTDM [31].

As the natural history of PTDM generally starts with severe hyperglycaemia (due to immunosuppressant induced beta cell dysfunction), followed by more modest hyperglycaemia as immunosuppression is tapered, early insulin therapy is frequently required (see section 6.0). One study aimed to address whether early insulin therapy could

be effective in preventing PTDM [32]. This study randomised 50 patients with hyperglycaemia in the first three weeks following renal transplantation to early basal insulin therapy versus standard care and found a 73% lower risk for development of PTDM. The authors suggest that insulin may protect the β -cells from stress hyperglycaemia (glucose toxicity) and calcineurin inhibitor toxicity. Larger studies are awaited.

Hepatitis C is a significant risk factor for the development of PTDM, and clearance of hepatitis C prior to transplantation may be possible with new drugs. A study of 14 patients with hepatitis C treated with α -interferon prior to renal transplantation showed a lower incidence of PTDM compared to a control group of 40 patients who were untreated [9]. A further study of 16 renal transplant recipients with hepatitis C who received interferon and had a sustained virologic response, showed that none developed PTDM over two years follow up [33].

Choice of immunosuppressive regimen may also reduce risk of PTDM in high risk individuals. In a study of the use of 1209 patients treated with belatacept, a selective c-stimulation blocker, versus standard immunosuppression with ciclosporin, use of low intensity belatacept was associated with a lower risk for the development of PTDM [34].

8.0 PTDM CONSIDERATIONS IN THE NON-RENAL SETTING

8.1 Recommendations

1. Organ-specific factors should be considered when counselling patients for their risk of PTDM prior to solid organ transplantation (Grade 1B)
2. The diagnosis of PTDM should be consistent across different solid organ transplant settings, with organ-specific caveats in mind to determine the optimal diagnostic test (e.g. accuracy of HbA_{1c}) (Grade 1C)
3. The management of PTDM should be consistent across different solid organ transplant settings, with organ-specific caveats in mind to determine the optimal management strategy (Grade 1B)

8.2 Areas for future research

1. What are the long-term outcomes for solid organ transplant recipients who develop PTDM?
2. Is the evolution on abnormal glucose metabolism post-transplantation different among different solid organ transplant settings?
3. Should solid organ transplant recipients receive the same management intervention strategy?

8.3 Audit recommendations

1. What proportion of non-renal solid organ transplant patients are risk assessed for the development of PTDM prior to transplantation?
2. What proportion of non-renal solid organ transplant patients are screened for post-transplant hyperglycaemia and PTDM?
3. What proportion of patients undergoing non-renal solid organ transplants have good glycaemic control as determined by their individualised glycaemic target?

8.4 Overview

Whilst the majority of published articles in the area of PTDM relate to renal transplantation, it is important to consider PTDM in the setting on non-renal transplantation [1]. Shared generic and transplant-specific risk factors mean PTDM remains a significant medical complication after all forms of SOT. General considerations are translatable across different solid organ settings, but there are some unique aspects to take into consideration with each organ concerning the diagnosis, prevention and management of PTDM.

8.5 PTDM after liver transplantation

8.5.1 Epidemiology and outcomes

The risk of developing PTDM after liver transplantation is significant, with registry data suggesting rates of up to 40% within five years [1-3]. Whilst liver transplant recipients share the same generic and many transplant-specific risk factors for development of PTDM, there are some unique considerations that lead to such high incidence after liver transplantation. For example, non-alcoholic steatohepatitis (NASH) makes a greater contribution to the burden of end-stage liver disease and patients with NASH often share features of the metabolic syndrome [4]. Transplant registry data from the United States has shown liver transplant recipients with NASH are more likely to develop PTDM [5]. Similarly, hepatitis C is a common cause of end-stage liver disease and an independent risk factor for development of PTDM after liver transplantation [6]. These aetiological factors likely explain why incidence of PTDM is highest after liver transplantation compared to other SOT [1]. However, no study after liver transplantation has utilised the OGTT for diagnostic purposes and the likely burden of PTDM and pre-diabetes may be higher than expected.

While single centre studies have shown conflicting results with regards to mortality outcome for liver transplant recipients who develop PTDM [3,7], registry data from Taiwan has shown increased mortality for liver transplant recipients with PTDM [8]. In a retrospective single-centre study of 994 liver transplant recipients from the United States, 16% had transient PTDM and 20% had sustained PTDM after liver transplant surgery with increased cumulative incidence of cardiovascular events and death associated with sustained PTDM [9].

8.5.2 Liver transplant caveats for diagnosis and management

As the liver has a major role in glucose metabolism, hyperglycaemia in early liver transplantation is common. PTDM diagnostic classification should remain the same for liver transplant recipients, but there are some specific considerations. Many liver transplant recipients will have renal impairment and therefore the same precautions are required for interpretation of HbA_{1c} [10]. In addition, interpretation of HbA_{1c} in the context of advanced liver disease may not be appropriate due to altered erythrocyte presentation [11], and therefore should be interpreted with caution if the liver allograft has sub-optimal function.

Management of diabetes in the setting of liver impairment can be difficult as the liver is the major site of metabolism for many anti-diabetic medications. Therefore, it is important to adjust the choice of pharmacological therapy on an individual basis after liver transplantation based upon the functional status of the liver allograft [12].

8.6 PTDM after heart transplantation

8.6.1 Epidemiology and outcomes

Registry data from South Korea and the Netherlands have reported PTDM rates of 25-28% and 20% respectively after five years post heart transplantation [13,14], with shared risk factors for its development as other SOT recipients [15]. Data with regards to outcomes is more limited. Diabetes is known to be a risk factor for death within a year of heart transplantation (hazard ratio 1.37, 95% CI 1.15-1.62), but this does not distinguish between pre-transplant versus PTDM [16]. In a South Korean study including 390 heart transplant recipients, patients with PTDM (determined by OGTT) had a similar risk of mortality as those with pre-existing diabetes mellitus, both of which were two-fold higher than heart transplant recipients without diabetes [13].

8.6.2 Heart transplant caveats for diagnosis and management

While there are no specific diagnostic considerations for detection of PTDM in heart transplant recipients, there are management considerations in the context of heart failure due to sub-optimal heart allograft function. While the majority of pharmacological interventions are safe, the use of thiazolidinediones and saxagliptin should be avoided due to a propensity to heart failure [17]. The propensity for renal impairment and hyperkalaemia

increases in the setting of heart failure and should lead to individualised pharmacological therapy for heart transplant recipients if there is sub-optimal heart allograft function.

8.7 PTDM after lung transplantation

8.7.1 Epidemiology and outcomes

Similar to heart transplantation, a significant proportion of lung transplant recipients develop PTDM. In a prospective single-centre study from Melbourne using OGTTs in 156 lung transplant recipients (25 with pre-existing diabetes), rates of PTDM after 3-months, 12-months and 24-months were 32%, 30 and 24% respectively in surviving patients [18]. Data from the International Society of Heart and Lung Transplant (ISHLT) registry and the United States shows PTDM incidence rates of approximately 30% and 40% among surviving lung transplant recipients by five years [19,20]. The incidence of PTDM appears greater in patients with a background of cystic fibrosis, with half of patients having diabetes prior to lung transplantation and half of the remaining individuals developing PTDM after lung transplantation [21]. Outcome data remains limited for lung transplant recipients who develop PTDM. A single-centre study from Melbourne analysing 210 lung transplant recipients demonstrated an increased risk of mortality with increasing degrees of hyperglycaemia but did not distinguish patients with pre-transplant and PTDM [22].

8.7.2 Lung transplant caveats for diagnosis and management

No specific caveats exist in the diagnosis or management of PTDM in the setting of lung transplantation above and beyond those already discussed in other sections.

REFERENCES

SECTION 1.0 REFERENCES

1. NHS Blood and Transplant. Annual Report on Kidney Transplantation. Report for 2017/18. Published September 2018.
<https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/12256/nhsbt-kidney-transplantation-annual-report-2017-2018.pdf>
2. Byrne C, Caskey F, Castledine C, Davenport A, Dawnay A, Fraser S, Maxwell H, Medcalf JF, Wilkie M, Williams AJ. UK Renal Registry 20th Annual Report of the Renal Association *Nephron* 2018;139 (suppl 1)
3. Saran R, Li Y, Robinson B, et al. US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States. *Am J Kidney Dis.* 2015;66 (suppl 1):S1-S306.
4. Rajapurkar MM, John GT, Kirpalani AL et al. What we know about chronic kidney disease in India: first report of the Indian CKD registry. *BMC Nephrology* 2012;13:10.
5. Starzl TE, Marchioro TL, Rifkind D, Holmes JH, Rowlands DT Jr, Waddell WR. Factors in Successful Renal Transplantation. *Surgery* 1964;56:296-318.
6. Sharif A, Heckin M, de Vries APR et al. Proceedings from an international consensus meeting on posttransplant diabetes mellitus: recommendations and future directions. *Am J Transplant* 2014;14:1992-2000.

SECTION 2.0 REFERENCES

1. Davidson J, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. *Transplantation* 2003;75(10 Suppl):SS3-24.
2. Arner P, et al. Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high-dose corticosteroid therapy. *Diabetes Care* 1983;6(1):23-5.
3. Hjelmessaeth J, et al. New-onset posttransplantation diabetes mellitus: insulin resistance or insulinopenia? Impact of immunosuppressive drugs, cytomegalovirus and hepatitis C virus infection. *Curr Diabetes Rev* 2005;1(1):1-10.
4. Yates CJ, et al. New-onset diabetes after kidney transplantation-changes and challenges. *Am J Transplant* 2012;12(4):820-8.
5. McCaughan JA, Courtney AE. The clinical course of kidney transplant recipients after 20 years of graft function. *Am J Transplant* 2015;15(3):734-40.
6. Sharif A, et al. Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. *J Am Soc Nephrol* 2011;22(11):2107-18.
7. Valderhaug TG, et al. Reduced incidence of new-onset posttransplantation diabetes mellitus during the last decade. *Transplantation* 2007;84(9):1125-30.
8. Hagen M, et al. A 6-year prospective study on new onset diabetes mellitus, insulin release and insulin sensitivity in renal transplant recipients. *Nephrol Dial Transplant* 2003;18(10):2154-9.
9. Porrini EL, et al. Clinical evolution of post-transplant diabetes mellitus. *Nephrol Dial Transplant* 2016;31(3):495-505.

10. Dienemann T, et al. Long-term patient survival and kidney allograft survival in post-transplant diabetes mellitus: a single-center retrospective study. *Transpl Int* 2016;29(9):1017-28.
11. Eide IA, et al. Mortality risk in post-transplantation diabetes mellitus based on glucose and HbA1c diagnostic criteria. *Transpl Int* 2016;29(5):568-78.
12. Eide IA, et al. Associations Between Posttransplantation Diabetes Mellitus and Renal Graft Survival. *Transplantation* 2017;101(6):1282-1289.
13. Kasiske BL, et al. Diabetes mellitus after kidney transplantation in the United States. *Am J Transplant* 2003;3(2):178-85.
14. Cosio FG, et al. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. *Kidney Int* 2002;62(4):1440-6.
15. Cole EH, et al. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. *Clin J Am Soc Nephrol* 2008;3(3):814-21.
16. Gaynor JJ, et al. Single-centre study of 628 adult, primary kidney transplant recipients showing no unfavourable effect of new-onset diabetes after transplant. *Diabetologia* 2015;58(2):334-45.
17. Kuo HT, et al. Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database. *Am J Kidney Dis* 2010;56(6):1127-39.
18. Matas AJ, et al. Posttransplant diabetes mellitus and acute rejection: impact on kidney transplant outcome. *Transplantation* 2008;85(3):338-43.
19. Valderhaug TG, et al. Early posttransplantation hyperglycemia in kidney transplant recipients is associated with overall long-term graft losses. *Transplantation* 2012;94(7):714-20.

20. Howell M, et al. Important outcomes for kidney transplant recipients: a nominal group and qualitative study. *Am J Kidney Dis* 2012;60(2):186-96.
21. Johal S, et al. Pre-existing diabetes is a risk factor for increased rates of cellular rejection after kidney transplantation: an observational cohort study. *Diabet Med* 2017;34(8):1067-1073.
22. Wauters RP, et al. Cardiovascular consequences of new-onset hyperglycemia after kidney transplantation. *Transplantation* 2012;94(4):377-82.
23. Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. *J Am Soc Nephrol* 2005;16(2):496-506.
24. Hjeltnes J, et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. *Kidney Int* 2006;69(3):588-95.
25. Stoumpos S, Jardine AG, Mark PB, Cardiovascular morbidity and mortality after kidney transplantation. *Transpl Int* 2015;28(1):10-21.
26. Burroughs TE, et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. *Transplantation* 2007;83(8):1027-34.
27. Londero TM, et al. Microvascular Complications of Posttransplant Diabetes Mellitus in Kidney Transplant Recipients: A Longitudinal Study. *J Clin Endocrinol Metab* 2019;104(2):557-567.

SECTION 3.0 REFERENCES

1. Sharif A, Baboolal K. Risk factors for new-onset diabetes after kidney transplantation. *Nat Rev Nephrol* 2010;6(7):415-23.
2. Hecking M, et al. Novel views on new-onset diabetes after transplantation: development, prevention and treatment. *Nephrol Dial Transplant*, 2013;28(3):550-66.
3. Hamer RA, et al. Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation. *Transplantation*, 2007;83(1):36-40.
4. de Mattos AM, et al. Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation. *Kidney Int* 2005;67(2):714-20.
5. Pietrzak-Nowacka M, et al. Autosomal dominant polycystic kidney disease is not a risk factor for post-transplant diabetes mellitus. Matched-pair design multicenter study. *Arch Med Res* 2008;39(3):312-9.
6. Ruderman I, et al. New onset diabetes after kidney transplantation in autosomal dominant polycystic kidney disease: a retrospective cohort study. *Nephrology (Carlton)* 2012;17(1):89-96.
7. Bayer ND, et al. Association of metabolic syndrome with development of new-onset diabetes after transplantation. *Transplantation* 2010;90(8):861-6.
8. Cheungpasitporn W, et al. The Risk for New-Onset Diabetes Mellitus after Kidney Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Meta-Analysis. *Can J Diabetes* 2016;40(6):521-528.
9. Zaccardi F, et al. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. *Postgrad Med J* 2016;92(1084):63-9.

10. Kahn SE, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. *Diabetes* 1993;42(11):1663-72.
11. Kahn SE, et al. Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. *Diabetes* 1989;38(5):562-8.
12. Perkoff GT, et al. Mechanism of impaired glucose tolerance in uremia and experimental hyperazotemia. *Diabetes* 1958;7(5):375-83.
13. DeFronzo RA, et al. Insulin resistance in uremia. *J Clin Invest* 1981;67(2):563-8.
14. Alsahli M, Gerich JE. Renal glucose metabolism in normal physiological conditions and in diabetes. *Diabetes Res Clin Pract* 2017;133:1-9.
15. Rabkin R, Ryan MP, Duckworth WC. The renal metabolism of insulin. *Diabetologia* 1984;27(3):351-7.
16. Duckworth WC. Insulin degradation: mechanisms, products, and significance. *Endocr Rev* 1988;9(3):319-45.
17. Arem R. Hypoglycemia associated with renal failure. *Endocrinol Metab Clin North Am*, 1989;18(1):103-21.
18. Meyer C, Dostou JM, Gerich JE. Role of the human kidney in glucose counterregulation. *Diabetes* 1999;48(5):943-8.
19. Orsi E, Grancini V, Menini S, Aghemo A, Pugliese G. Hepatogenous diabetes: Is it time to separate it from type 2 diabetes? *Liver International* 2017; 37: 950-962.
20. Grancini V, Trombetta M, Lunati ME, et al. Contribution of β -cell dysfunction and insulin resistance to cirrhosis-associated diabetes: role of severity of liver disease. *J Hepatol*. 2015;63:1484–1490.

21. Marselli L, De Simone P, Morganti R, et al. Frequency and characteristics of diabetes in 300 pre-liver transplant patients. *Nutr Metab Cardiovasc Dis.* 2016;26:441–442.
22. Ekstrand AV, et al. Insulin resistance and insulin deficiency in the pathogenesis of posttransplantation diabetes in man. *Transplantation* 1992;53(3):563-9.
23. Standards of medical care in diabetes-2006. *Diabetes Care* 2006;29 Suppl 1:S4-42.
24. Hagen M, et al. A 6-year prospective study on new onset diabetes mellitus, insulin release and insulin sensitivity in renal transplant recipients. *Nephrol Dial Transplant* 2003;18(10):2154-9.
25. Montori VM, et al. Posttransplantation diabetes: a systematic review of the literature. *Diabetes Care* 2002;25(3):583-92.
26. Heisel O, et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. *Am J Transplant* 2004;4(4):583-95.
27. Vincenti F, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. *Am J Transplant* 2007;7(6):1506-14.
28. Duijnhoven EM, et al. Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. *J Am Soc Nephrol* 2001;12(3):583-8.
29. Tamura K, et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. *Transplantation* 1995;59(11):1606-13.
30. Weir MR, Fink JC. Risk for posttransplant Diabetes mellitus with current immunosuppressive medications. *Am J Kidney Dis* 1999;34(1):1-13.
31. Hirano Y, et al. Morphological and functional changes of islets of Langerhans in FK506-treated rats. *Transplantation* 1992;53(4):889-94.

32. Markell M. New-onset diabetes mellitus in transplant patients: pathogenesis, complications, and management. *Am J Kidney Dis* 2004;43(6):953-65.
33. Chakkeria HA, et al. Relationship between inpatient hyperglycemia and insulin treatment after kidney transplantation and future new onset diabetes mellitus. *Clin J Am Soc Nephrol* 2010;5(9):1669-75.
34. Hecking M, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. *J Am Soc Nephrol* 2012;23(4):739-49.
35. Porrini EL, et al. Clinical evolution of post-transplant diabetes mellitus. *Nephrol Dial Transplant* 2016;31(3):495-505.
36. McCaughan JA, McKnight AJ, Maxwell AP. Genetics of new-onset diabetes after transplantation. *J Am Soc Nephrol* 2014;25(5):1037-49.
37. Sharif A, Baboolal K. Metabolic syndrome and solid-organ transplantation. *Am J Transplant* 2010;10(1):12-7.

SECTION 4.0 REFERENCES

1. Davidson J, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. *Transplantation* 2003;75(10 Suppl):S33-24.
2. Fang J, et al. Diabetes mellitus after renal transplantation. *Transplant Proc* 1998;30(7):3027-8.
3. USRDS. US Renal Data System, Annual Report 2011. http://www.usrds.org/2011/view/v2_07.asp. 2011; Available from: http://www.usrds.org/2011/view/v2_07.asp.
4. Sharif A, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. *Am J Transplant* 2014;14(9):1992-2000.
5. Hur KY, et al. Risk factors associated with the onset and progression of posttransplantation diabetes in renal allograft recipients. *Diabetes Care* 2007;30(3):609-15.
6. Valderhaug TG, et al. The association of early post-transplant glucose levels with long-term mortality. *Diabetologia* 2011;54(6):1341-9.
7. Hecking M, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. *J Am Soc Nephrol* 2012;23(4):739-49.
8. Chakkera HA, et al. Hyperglycemia during the immediate period after kidney transplantation. *Clin J Am Soc Nephrol* 2009;4(4):853-9.
9. Cosio FG, et al. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. *Kidney Int* 2001;59(2):732-7.
10. Porrini EL, et al. Clinical evolution of post-transplant diabetes mellitus. *Nephrol Dial Transplant* 2016;31(3):495-505.

11. ADA. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2010;33 Suppl 1:S62-9.
12. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. *Diabetes Care* 2006;29(5):1130-9.
13. Unwin N, et al. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. *Diabet Med* 2002;19(9):708-23.
14. Sharif A, Moore RH, Baboolal K. The use of oral glucose tolerance tests to risk stratify for new-onset diabetes after transplantation: An underdiagnosed phenomenon. *Transplantation* 2006;82(12):1667-72.
15. Hecking M, et al. Glucose Metabolism After Renal Transplantation. *Diabetes Care* 2013;36(9):2763-2771
16. The DECODE-study group. European Diabetes Epidemiology Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. Diabetes Epidemiology: Collaborative analysis of Diagnostic Criteria in Europe. *Diabetologia* 1999;42(6):647-54.
17. Valderhaug TG, et al. Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. *Transplantation* 2009;88(3):429-34.
18. Mak RH. Impact of end-stage renal disease and dialysis on glycemic control. *Semin Dial* 2000;13(1):4-8.
19. Bergrem HA, et al. Undiagnosed diabetes in kidney transplant candidates: a case-finding strategy. *Clin J Am Soc Nephrol* 2010;5(4):616-22.
20. ADA. Standards of medical care in diabetes-2014. *Diabetes Care* 2014;37 Suppl 1:S14-80.

21. Shah A, et al. Home glucometer monitoring markedly improves diagnosis of post renal transplant diabetes mellitus in renal transplant recipients. *Transplantation* 2005;80(6):775-81.
22. Mollar-Puchades MA, et al. Diabetes mellitus after kidney transplantation: role of the impaired fasting glucose in the outcome of kidney transplantation. *J Endocrinol Invest*, 2009;32(3):263-6.
23. Pan XR, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. *Diabetes Care* 1997;20(4):537-44.
24. Healy GN, et al. Beneficial associations of physical activity with 2-h but not fasting blood glucose in Australian adults: the AusDiab study. *Diabetes Care* 2006;29(12):2598-604.
25. Sharif A, Moore R, Baboolal K. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. *Transplantation* 2008;85(3):353-8.
26. Werzowa J, et al. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial. *Transplantation* 2013;95(3):456-62.
27. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. *Diabetes Care* 2009;32(7):1327-34.
28. Bunn HF, et al. The biosynthesis of human hemoglobin A1c. Slow glycosylation of hemoglobin in vivo. *J Clin Invest* 1976;57(6):1652-9.
29. Davenport A, et al. Carbamylated hemoglobin: a potential marker for the adequacy of hemodialysis therapy in end-stage renal failure. *Kidney Int* 1996;50(4):1344-51.
30. De Marchi S, et al. More on the increase of hemoglobin A1 in chronic renal failure: the role of acidosis. *Nephron* 1983;35(1):49-53.

31. Chudnovsky Y, Khavari PA, Adams AE. Melanoma genetics and the development of rational therapeutics. *J Clin Invest* 2005;115(4):813-24.
32. Coban E, Ozdogan M, Timuragaoglu A. Effect of iron deficiency anemia on the levels of hemoglobin A1c in nondiabetic patients. *Acta Haematol* 2004;112(3):126-8.
33. Shah N, et al. Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors. *Transplantation* 2006;81(8):1112-8.
34. Hoban R, et al. Utility of HbA1c in the detection of subclinical post renal transplant diabetes. *Transplantation* 2006;81(3):379-83.
35. Shabir S, et al. Validity of glycated haemoglobin to diagnose new onset diabetes after transplantation. *Transpl Int* 2013;26(3):315-21.
36. Yates CJ, et al. Screening for new-onset diabetes after kidney transplantation: limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin. *Transplantation* 2013;96(8):726-31.
37. Tillmann FP, Rump LC, Quack I. HbA1c levels at 90 days after renal transplantation in non-diabetic recipients predict de novo pre-diabetes and diabetes at 1 and 3 years after transplantation. *Int Urol Nephrol* 2018;50(8):1529-1534.
38. Pimentel AL, Cavagnolli G, Camargo JL. Diagnostic accuracy of glycated hemoglobin for post-transplantation diabetes mellitus after kidney transplantation: systematic review and meta-analysis. *Nephrol Dial Transplant* 2017;32(3):565-572.
39. Ussif AM, et al. Validation of diagnostic utility of fasting plasma glucose and HbA1c in stable renal transplant recipients one year after transplantation. *BMC Nephrol* 2019;20(1):12.
40. Langendam M, et al. Continuous glucose monitoring systems for type 1 diabetes mellitus. *Cochrane Database Syst Rev* 2012.;1:CD008101.

41. Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. *Diabetes Technol Ther* 2009;11 Suppl 1:S55-67.
42. Thomas A, Heinemann L. Prediction of the risk to develop diabetes-related late complications by means of the glucose pentagon model: analysis of data from the juvenile diabetes research foundation continuous glucose monitoring study. *J Diabetes Sci Technol* 2012;6(3):572-80.
43. Werzowa J, et al. Glycemic variability and glucose control in post-transplant diabetes mellitus after renal transplantation. EASD annual conference, poster session. 2014. Vienna.
44. Yates CJ, et al. Divided dosing reduces prednisolone-induced hyperglycaemia and glycaemic variability: a randomized trial after kidney transplantation. *Nephrol Dial Transplant* 2014;29(3):698-705.
45. Pasti K, et al. Continuous glucose monitoring system (CGMS) in kidney-transplanted children. *Pediatr Transplant* 2013;17(5):454-60.
46. Rodriguez LM, Knight RJ, Heptulla RA. Continuous glucose monitoring in subjects after simultaneous pancreas-kidney and kidney-alone transplantation. *Diabetes Technol Ther*, 2010;12(5):347-51.
47. Wojtusciszyn A, et al. Continuous glucose monitoring after kidney transplantation in non-diabetic patients: early hyperglycaemia is frequent and may herald post-transplantation diabetes mellitus and graft failure. *Diabetes Metab* 2013;39(5):404-10.
48. Klonoff DC. Serum fructosamine as a screening test for type 2 diabetes. *Diabetes Technol Ther* 2000;2(4):537-9.
49. Baker JR, et al. Clinical usefulness of estimation of serum fructosamine concentration as a screening test for diabetes mellitus. *BMJ* 1983;287(6396):863-7.

50. Johnson RN, Metcalf PA, Baker JR. Fructosamine: a new approach to the estimation of serum glycosylprotein. An index of diabetic control. *Clin Chim Acta* 1983;127(1):87-95.
51. Lindsey CC, et al. A prospective, randomized, multicentered controlled trial to compare the annual glycemic and quality outcomes of patients with diabetes mellitus monitored with weekly fructosamine testing versus usual care. *Diabetes Technol Ther* 2004;6(3):370-7.
52. Morgan L, et al. Glycated proteins as indices of glycaemic control in diabetic patients with chronic renal failure. *Diabet Med* 1996;13(6):514-9.
53. Morgan LJ, et al. Glycated haemoglobin and fructosamine in non-diabetic subjects with chronic renal failure. *Nephrol Dial Transplant* 1990;5(10):868-73.
54. Vos FE, et al. Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring. *Nephrology (Carlton)* 2011;17(2):182-8.
55. Inaba M, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. *J Am Soc Nephrol* 2007;18(3):896-903.

SECTION 5.0 REFERENCES

1. Gupta S, Pollack T, Fulkerson C, Schmidt K, Oakes DJ, Molitch ME, Wallia A. Hyperglycemia in the Posttransplant Period: NODAT vs Posttransplant Diabetes Mellitus. *J Endocr Soc*. 2018;2(11):1314-1319. doi: 10.1210/js.2018-00227.
2. Langsford D, Obeyesekere V, Vogrin S, Teng J, MacIsaac RJ, Ward G, Alford F, Dwyer KM. A Prospective Study of Renal Transplant Recipients: A Fall in Insulin Secretion Underpins Dysglycemia After Renal Transplantation. *Transplant Direct*. 2016;7;2(11):e107.
3. Chakkera HA, Weil EJ, Castro J, Heilman RL, Reddy KS, Mazur MJ, Hamawi K, Mulligan DC, Moss AA, Mekeel KL, Cosio FG, Cook CB. Hyperglycemia during the immediate period after kidney transplantation. *Clin J Am Soc Nephrol*. 2009;4(4):853-9. doi: 10.2215/CJN.05471008.
4. Ke QH, Huang HT, Ling Q, Liu JM, Dong SY, He XX, Zhang WJ, Zheng SS. New-onset hyperglycemia immediately after liver transplantation: A national survey from China Liver Transplant Registry. *Hepatobiliary Pancreat Dis Int*. 2018;17(4):310-315. doi: 10.1016/j.hbpd.2018.08.005.
5. Wojtusciszyn A, Mourad G, Bringer J, Renard E. Continuous glucose monitoring after kidney transplantation in non-diabetic patients: early hyperglycaemia is frequent and may herald post-transplantation diabetes mellitus and graft failure. *Diabetes Metab*. 2013;39(5):404-10. doi: 10.1016/j.diabet.2012.10.007.
6. Chakkera HA, Knowler WC, Devarapalli Y, Weil EJ, Heilman RL, Dueck A, Mulligan DC, Reddy KS, Moss AA, Mekeel KL, Mazur MJ, Hamawi K, Castro JC, Cook CB. Relationship between inpatient hyperglycemia and insulin treatment after kidney transplantation and future new onset diabetes mellitus. *Clin J Am Soc Nephrol*. 2010;5(9):1669-75. doi: 10.2215/CJN.09481209

7. Maldonado F, Tapia G, Ardiles L. Early hyperglycemia: a risk factor for posttransplant diabetes mellitus among renal transplantrecipients. *Transplant Proc.* 2009;41(6):2664-7. doi: 10.1016/j.transproceed.2009.06.133.
8. Ganji MR, Charkhchian M, Hakemi M, Nederi GH, Solymanian T, Saddadi F, Amini M, Najafi I. Association of hyperglycemia on allograft function in the early period after renal transplantation. *Transplant Proc.* 2007;39(4):852-4.
9. Wallia A, Parikh ND, Molitch ME, Mahler E, Tian L, Huang JJ, Levitsky J. Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. *Transplantation.* 2010;89(2):222-6. doi: 10.1097/TP.0b013e3181c3c2ff.
10. Parekh J, Roll GR, Wisel S, Rushakoff RJ, Hirose R. Effect of moderately intense perioperative glucose control on renal allograft function: a pilot randomized controlled trial in renal transplantation. *Clin Transplant.* 2016;30(10):1242-1249. doi: 10.1111/ctr.12811.
11. Kek PC, Tan HC, Kee TY, Goh SY, Bee YM. Day 1 post-operative fasting hyperglycemia may affect graft survival in kidney transplantation. *Ann Transplant.* 2013;18:265-72. doi: 10.12659/AOT.883937.
12. van den Berg TJ, Bogers H, Vriesendorp TM, Surachno JS, DeVries JH, ten Berge IJ, Hoekstra JB. No apparent impact of increased post-operative blood glucose levels on clinical outcome in kidney transplant recipients. *Clin Transplant.* 2009;23(2):256-63.
13. Giráldez E, Varo E, Guler I, Cadarso-Suarez C, Tomé S, Barral P, Garrote A, Gude F. Post-operative stress hyperglycemia is a predictor of mortality in liver transplantation. *Diabetol Metab Syndr.* 2018;10:35. doi: 10.1186/s13098-018-0334-5.
14. Hecking M, Haidinger M, Döller D, Werzowa J, Tura A, Zhang J, Tekoglu H, Pleiner J, Wrba T, Rasoul-Rockenschaub S, Mühlbacher F, Schmaldienst S, Druml W, Hörl WH, Krebs M, Wolzt M, Pacini G, Port FK, Säemann MD. Early basal insulin therapy

- decreases new-onset diabetes after renal transplantation. *J Am Soc Nephrol*. 2012;23(4):739-49. doi: 10.1681/ASN.2011080835.
15. Werzowa JM, Säemann MD, Mohl A, Bergmann M, Kaltenecker CC, Brozek W, Thomas A, Haidinger M, Antlanger M, Kovarik JJ, Kopecky C, Song P, Budde K, Pascual J, Hecking M. A randomized controlled trial-based algorithm for insulin-pump therapy in hyperglycemic patients early after kidney transplantation. *PLoS One*. 2018;13(3):e0193569. doi: 10.1371/journal.pone.0193569.
 16. Wallia A, Schmidt K, Oakes DJ, Pollack T, Welsh N, Kling-Colson S, Gupta S, Fulkerson C, Aleppo G, Parikh N, Levitsky J, Norvell JP, Rademaker A, Molitch ME. Glycemic Control Reduces Infections in Post-Liver Transplant Patients: Results of a Prospective, Randomized Study. *J Clin Endocrinol Metab*. 2017;102(2):451-459. doi: 10.1210/jc.2016-3279.
 17. Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Miñambres I, Gomez-Huelgas R. Glucocorticoid-induced hyperglycemia. *J Diabetes*. 2014;6(1):9-20. doi: 10.1111/1753-0407.12090.
 18. Joint British Diabetes Societies. Management of hyperglycaemia and steroid (glucocorticoid) therapy. http://www.diabetologists-abcd.org.uk/JBDS/JBDS_IP_Steroids.pdf
 19. Abbott KC, Bernet VJ, Agodoa LY, Yuan CM. Diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome after renal transplantation in the United States. *BMC Endocr Disord* 2003;3:1.
 20. Joint British Diabetes Societies Management of adults with diabetes undergoing surgery and elective procedures: improving standards. http://www.diabetologists-abcd.org.uk/JBDS/JBDS_IP_Surgery_Adults_Full.pdf
 21. Mesotten D, Preiser JC, Kosiborod M. Glucose management in critically ill adults and children. *Lancet Diabetes Endocrinol*. 2015;3(9):723-33. doi: 10.1016/S2213-8587(15)00223-5.

22. Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenström A, Wedel H, Welin L. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. *J Am Coll Cardiol*. 1995;26(1):57-65.

23. Hermayer KL, Egidi MF, Finch NJ, Baliga P, Lin A, Kettinger L, Biggins S, Carter RE. A randomized controlled trial to evaluate the effect of glycemic control on renal transplantation outcomes. *J Clin Endocrinol Metab*. 2012;97(12):4399-406. doi: 10.1210/jc.2012-1979.

24. Revanur VK, Jardine AG, Kingsmore DB, Jaques BC, Hamilton DH, Jindal RM. Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. *Clin Transplant*. 2001;15(2):89-94.

25. Miles AM, Sumrani N, Horowitz R, Homel P, Maursky V, Markell MS, Distant DA, Hong JH, Sommer BG, Friedman EA. Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes? *Transplantation*. 1998;65(3):380-4.

26. Siraj ES, Abacan C, Chinnappa P, Wojtowicz J, Braun W. Risk factors and outcomes associated with posttransplant diabetes mellitus in kidney transplant recipients. *Transplant Proc*. 2010;42(5):1685-9. doi: 10.1016/j.transproceed.2009.12.062.

27. Kuo HT, Sampaio MS, Vincenti F, Bunnapradist S. Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database. *Am J Kidney Dis*. 2010;56(6):1127-39. doi: 10.1053/j.ajkd.2010.06.027.

28. Burroughs TE, Swindle J, Takemoto S, Lentine KL, Machnicki G, Irish WD, Brennan DC, Schnitzler MA. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. *Transplantation*. 2007;83(8):1027-34.

29. Londero TM, Giaretta LS, Farenzena LP, Manfro RC, Canani LH, Lavinsky D, Leitão CB, Bauer AC. Microvascular Complications of Posttransplant Diabetes Mellitus in Kidney Transplant Recipients: A Longitudinal Study. *J Clin Endocrinol Metab.* 2019;104(2):557-567. doi: 10.1210/jc.2018-01521.

30. Nagib AM, Elsayed Matter Y, Gheith OA, Refaie AF, Othman NF, Al-Otaibi. Diabetic Nephropathy Following Post-transplant Diabetes Mellitus. *Exp Clin Transplant.* 2019;17(2):138-146. doi: 10.6002/ect.2018.0157.

31. Kim YC, Shin N, Lee S, Hyuk H, Kim YH, Kim H, Park SK, Cho JH, Kim CD, Ha J, Chae DW, Lee JP, Kim YS. Effect of post-transplant glycemic control on long-term clinical outcomes in kidney transplant recipients with diabetic nephropathy: A multicenter cohort study in Korea. *PLoS One.* 2018;13(4):e0195566. doi: 10.1371/journal.pone.0195566.

32. Wiesbauer F, Heinze G, Regele H, Hörl WH, Schernthaner GH, Schwarz C, Kainz A, Kramar R, Oberbauer R. Glucose control is associated with patient survival in diabetic patients after renal transplantation. *Transplantation.* 2010;89(5):612-9. doi: 10.1097/TP.0b013e3181c6ffa4.

33. Ramirez S, Maaske J, Kim Y, Neagu V, DeLange S, Mazhari A, Gao W, Emanuele M, Emanuele N, Baldwin D, Mihailescu D. The Association Between Glycemic Control and Clinical Outcomes After Kidney Transplantation. *Endocrine Practice* 2014;20(9):894-900. <https://doi.org/10.4158/EP13463.OR>

34. Hackman KL, Snell GI, Bach LA. Poor Glycemic Control Is Associated With Decreased Survival in Lung Transplant Recipients. *Transplantation.* 2017;101(9):2200-2206. doi: 10.1097/TP.0000000000001555.

35. National Institute for Clinical Excellence. Type 2 diabetes in adults: management. <https://www.nice.org.uk/guidance/ng28>

36. American Diabetes Association. Glycaemic targets: standards of medical care in diabetes. *Diabetes Care* 2018; 41(Supplement 1): S55-S64. <https://doi.org/10.2337/dc18-S006>

37. Kasiske B, Zeier MG, Chapman JR et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. *Kidney Int.* 2010;77(4):299-311. doi: 10.1038/ki.2009.377.

38. ABCD/RA. Managing hyperglycaemia in patients with diabetes and diabetic nephropathy-chronic kidney disease. https://renal.org/wp-content/uploads/2017/07/ABCD%E2%80%93RA_Managing-glycaemia-guideline_Recommendations-summary_2018Publication.pdf

39. Vanhove T, Remijnsen Q, Kuypers D, Gillard P. Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus. *Transplant Rev (Orlando)*. 2017;31(2):69-77. doi: 10.1016/j.trre.2016.09.001.

40. Costa B, Moratelli L, Silva LB, et al. Body mass index in the first year after kidney transplantation. *Transplant Proc.* 2014;46(6):1750–52.

41. Hap K, Madziarska K, Hap W, Zmonarski S, Zielińska D, Kamińska D, Banasik M, Kościelska-Kasprzak K, Klinger M, Mazanowska O. Are Females More Prone Than Males to Become Obese After Kidney Transplantation? *Ann Transplant.* 2019;24:57-61. doi: 10.12659/AOT.912096.

42. Moore LW, Gaber AO. Patterns of early weight change after renal transplantation. *J Renal Nutr* 1996;6(1):21-25.

43. Aksoy N. Weight Gain After Kidney Transplant. *Exp Clin Transplant.* 2016;14(Suppl 3):138-140.

44. Orazio L, Chapman J, Isabel NM, Campbell KL. Nutrition care for renal transplant recipients: an evaluation of service delivery and outcomes. *J Ren Care*. 2014;40(2):99-106. doi: 10.1111/jorc.12055.
45. Patel MG. The effect of dietary intervention on weight gains after renal transplantation. *J Ren Nutr*. 1998;8(3):137-41.
46. Bzoma B, Konopa J, Chamienia A, Łukiański M, Kobiela J, Śledziński Z, Dębska-Ślizień A. New-onset Diabetes Mellitus After Kidney Transplantation - A Paired Kidney Analysis. *Transplant Proc*. 2018;50(6):1781-1785. doi: 10.1016/j.transproceed.2018.02.119.
47. Wilcox J, Waite C, Tomlinson L, Driscoll J, Karim A, Day E, Sharif A. Comparing glycaemic benefits of active versus passive lifestyle intervention in kidney allograft recipients (CAVIAR): a randomised controlled trial. *Transplantation* 2019 doi: 10.1097/TP.0000000000002969
48. Pedrollo EF, Nicoletto BB, Carpes LS, de Freitas JMC, Buboltz JR, Forte CC, Bauer AC, Manfro RC, Souza GC, Leitão CB. Effect of an intensive nutrition intervention of a high protein and low glycemic-index diet on weight of kidney transplant recipients: study protocol for a randomized clinical trial. *Trials*. 2017;18(1):413. doi: 10.1186/s13063-017-2158-2.
49. Klaassen G, Zelle DM, Navis GJ, Dijkema D, Bemelman FJ, Bakker SJL, Corpeleijn E. Lifestyle intervention to improve quality of life and prevent weight gain after renal transplantation: Design of the Active Care after Transplantation (ACT) randomized controlled trial. *BMC Nephrol*. 2017 Sep 15;18(1):296. doi: 10.1186/s12882-017-0709-0.
50. Osté MC, Corpeleijn E, Navis GJ, Keyzer CA, Soedamah-Muthu SS, van den Berg E, Postmus D, de Borst MH, Kromhout D, Bakker SJ. Mediterranean style diet is associated with low risk of new-onset diabetes after renal transplantation. *BMJ Open Diabetes Res Care*. 2017 Jan 13;5(1):e000283. doi: 10.1136/bmjdr-2016-000283

51. Knowler WC, Barrett-Connor E, Fowler SE, et al., Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002;346:393–403

52. Tuomilehto J, Lindström J, Eriksson JG, et al., Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 2001;344:1343–1350

53. Vest LS, Koraishy FM, Zhang Z, Lam NN, Schnitzler MA, Dharnidharka VR, Axelrod D, Naik AS, Alhamad TA, Kasiske BL, Hess GP, Lentine KL. Metformin use in the first year after kidney transplant, correlates, and associated outcomes in diabetic transplant recipients: A retrospective analysis of integrated registry and pharmacy claims data. *Clin Transplant*. 2018;32(8):e13302. doi: 10.1111/ctr.13302.

54. Stephen J, Anderson-Haag TL, Gustafson S, Snyder JJ, Kasiske BL, Israni AK. Metformin use in kidney transplant recipients in the United States: an observational study. *Am J Nephrol*. 2014;40(6):546-53. doi: 10.1159/000370034.

55. Kurian B, Joshi R, Helmuth A. Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients. *Endocr Pract*. 2008 Nov;14(8):979-84.

56. Sharif A. Should metformin be our antiglycemic agent of choice post-transplantation? *Am J Transplant*. 2011 Jul;11(7):1376-81. doi: 10.1111/j.1600-6143.2011.03550.x.

57. Haidinger M, Antlanger M, Kopecky C, Kovarik JJ, Säemann MD, Werzowa J. Post-transplantation diabetes mellitus: evaluation of treatment strategies. *Clin Transplant*. 2015;29(5):415-24. doi: 10.1111/ctr.12541.

58. Türk T, Pietruck F, Dolff S, Kribben A, Janssen OE, Mann K, Philipp T, Heemann U, Witzke O. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. *Am J Transplant*. 2006;6(4):842-6.

59. Luther P, Baldwin D Jr. Pioglitazone in the management of diabetes mellitus after transplantation. *Am J Transplant.* 2004;4(12):2135-8.
60. Han SJ, Hur KY, Kim YS, Kang ES, Kim MS, Kwak JY, Kim DJ, Choi SH, Cha BS, Lee HC. Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in non-diabetic renal allograft recipients. *Nephrol Dial Transplant* 2010;25:976-84
61. Baldwin D Jr, Duffin KE. Rosiglitazone treatment of diabetes mellitus after solid organ transplantation. *Transplantation.* 2004;77(7):1009-14.
62. Voytovich MH, Simonsen C, Jenssen T, Hjelmessaeth J, Asberg A, Hartmann A. Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients. *Nephrol Dial Transplant.* 2005;20(2):413-8.
63. Villanueva G, Baldwin D. Rosiglitazone therapy of posttransplant diabetes mellitus. *Transplantation.* 2005;80(10):1402-5.
64. Åberg F, Koljonen V, Nikkilä K, Boyd S, Arola J, Isoniemi H. Thiazolidinedione therapy versus lifestyle recommendation in the treatment of post-liver transplant graft steatosis. *Ann Transplant.* 2014;19:389-96. doi: 10.12659/AOT.890664.
65. Jin L, Lim SW, Jin J, Chung BH, Yang CW. Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus. *Transl Res.* 2016;174:122-39. doi: 10.1016/j.trsl.2016.03.012.
66. Boerner BP, Miles CD, Shivaswamy V. Efficacy and safety of sitagliptin for the treatment of new-onset diabetes after renal transplantation. *Int J Endocrinol.* 2014;617638. doi: 10.1155/2014/617638.

67. Strøm Halden TA, Åsberg A, Vik K, Hartmann A, Jenssen T. Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. *Nephrol Dial Transplant*. 2014;29(4):926-33. doi: 10.1093/ndt/gft536.
68. Lane JT, Odegaard DE, Haire CE, Collier DS, Wrenshall LE, Stevens RB. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. *Transplantation*. 2011;92(10):e56-7. doi: 10.1097/TP.0b013e3182347ea4.
69. Sanyal D, Gupta S, Das P. A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting. *Indian J Endocrinol Metab*. 2013;17(Suppl 1):S203-5. doi: 10.4103/2230-8210.119572.
70. Haidinger M, Werzowa J, Hecking M, Antlanger M, Stemer G, Pleiner J, Kopecky C, Kovarik JJ, Döller D, Pacini G, Säemann MD. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation--a randomized, double-blind, placebo-controlled trial. *Am J Transplant*. 2014;14(1):115-23. doi: 10.1111/ajt.12518.
71. Bae J, Lee MJ, Choe EY, Jung CH, Wang HJ, Kim MS, Kim YS, Park JY, Kang ES. Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study. *Endocrinol Metab (Seoul)*. 2016;31(1):161-7. doi: 10.3803/EnM.2016.31.1.161.
72. Soliman AR, Fathy A, Khashab S, Shaheen N, Soliman MA. Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant. *Exp Clin Transplant*. 2013;11(6):494-8.
73. Guardado-Mendoza R, Evia-Viscarra ML, Jiménez-Ceja LM, Durán-Pérez EG, Aguilar-García A. Linagliptin plus insulin for hyperglycemia immediately after renal transplantation: A comparative study. *Diabetes Research & Clinical Practice* 2019;156:107864 DOI: <https://doi.org/10.1016/j.diabres.2019.107864>

74. Gueler I, Mueller S, Helmschrott M, Oeing CU, Erbel C, Frankenstein L, Gleißner C, Ruhparwar A, Ehlermann P, Dengler TJ, Katus HA, Doesch AO. Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation. *Drug Des Devel Ther.* 2013;7:297-303. doi: 10.2147/DDDT.S43092.

75. Werzowa J, Hecking M, Haidinger M, Lechner F, Döller D, Pacini G, Stermer G, Pleiner J, Frantal S, Säemann MD. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial. *Transplantation.* 2013;95(3):456-62. doi: 10.1097/TP.0b013e318276a20e.

76. Abdelaziz TS, Ali AY, Fatthy M. Efficacy and safety of Dipeptidyl Peptidase-4 Inhibitors in kidney transplant recipients with Post-transplant diabetes mellitus (PTDM) - a systematic review and Meta-Analysis. *Curr Diabetes Rev.* 2019. doi: 10.2174/1573399815666190321144310.

77. Boye KS, Botros FT, Haupt A, Woodward B, Lage MJ. Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population. *Diabetes Ther.* 2018;9(2):637-650. doi: 10.1007/s13300-018-0377-5.

78. Halden TA, Egeland EJ, Åsberg A, Hartmann A, Midtvedt K, Khiabani HZ, Holst JJ, Knop FK, Hornum M, Feldt-Rasmussen B, Jenssen T. GLP-1 Restores Altered Insulin and Glucagon Secretion in Posttransplantation Diabetes. *Diabetes Care.* 2016;39(4):617-24. doi: 10.2337/dc15-2383.

79. Pinelli NR, Patel A, Salinitri FD. Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series. *Diabetes Care.* 2013;36(10):e171-2. doi: 10.2337/dc13-1066.

80. Liou JH, Liu YM, Chen CH. Management of Diabetes Mellitus With Glucagonlike Peptide-1 Agonist Liraglutide in Renal Transplant Recipients: A Retrospective Study. *Transplant Proc.* 2018;50(8):2502-2505. doi: 10.1016/j.transproceed.2018.03.087.
81. Singh P, Pesavento TE, Washburn K, Walsh D, Meng S. Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients. *Diabetes Obes Metab.* 2018 doi: 10.1111/dom.13619.
82. Kluger AY, Tecson KM, Barbin CM, Lee AY, Lerma EV, Rosol ZP, Rangaswami J, Lepore NE, Cobble ME, McCullough PA. Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review. *Rev Cardiovasc Med.* 2018;19(2):41-49. doi: 10.31083/j.rcm.2018.02.907.
83. Liu J, Li L, Li S, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. *Sci Rep.* 2017;7(1):2824.
84. Abbott KC, Swanson SJ, Richter ER, et al. Late urinary tract infection after renal transplantation in the United States. *Am J Kidney Dis.* 2004;44(2):353-362.
85. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. *Diabetes Care.* 2015;38(9):1638-1642.
86. Schwaiger E, Burghart L, Signorini L, Ristl R, Kopecky C, Tura A, Pacini G, Wrba T, Antlanger M, Schmaldienst S, Werzowa J, Säemann MD, Hecking M. Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. *Am J Transplant.* 2019 Mar;19(3):907-919. doi: 10.1111/ajt.15223.
87. Halden TAS, Kvitne KE, Midtvedt K, Rajakumar L, Robertsen I, Brox J, Bollerslev J, Hartmann A, Åsberg A, Jenssen T. Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus. *Diabetes Care.* 2019;42(6):1067-1074. doi: 10.2337/dc19-0093.

88. Shah M, Virani Z, Rajput P, Shah B. Efficacy and Safety of Canagliflozin in Kidney Transplant Patients. *Indian J Nephrol.* 2019;29(4):278-281. doi: 10.4103/ijn.IJN_2_18.
89. Tsai HI, Liu FC, Lee CW, Kuo CF, See LC, Chung TT, Yu HP. Cardiovascular disease risk in patients receiving organ transplantation: a national cohort study. *Transpl Int.* 2017 Nov;30(11):1161-1171. doi: 10.1111/tri.13010. Epub 2017 Aug 3.
90. Israni AK, Snyder JJ, Skeans MA et al. and the PORT investigators. Predicting coronary heart disease after kidney transplantation. Patient Outcomes after Renal Transplantation (PORT) study. *Am J Transplant* 2010;10:338-53
91. Corbett C, Armstrong MJ, Neuberger J. Tobacco smoking and solid organ transplantation. *Transplantation* 2012;94:979-87
92. Pan A, Wang Y, Talaei M, Hu FB, Wu T. Relation of active, passive and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol* 2015;3:958-67
93. Warden BA, Duell PB. Management of dyslipidemia in adult solid organ transplant recipients. *J Clin Lipidol.* 2019;13(2):231-245. doi: 10.1016/j.jacl.2019.01.011.
94. Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. *Lancet.* 2003;361(9374):2024-31.
95. Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, Hegbrant J, Strippoli GF. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. *Cochrane Database Syst Rev.* 2014;(1):CD005019.
96. Opelz G, Zeier M, Laux G, Morath C, Döhler B. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme

inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. *J Am Soc Nephrol*. 2006;17(11):3257-62.

97. Dasgupta I, Banerjee D, Chowdhury TA, De P, Wahba M, Bain S, Frankel A, Fogarty D, Pokrajac A, Winocour P. Association of British Clinical Diabetologists and Renal Association clinical guidelines: hypertension management and renin-angiotensin aldosterone blockade in patients with diabetes, nephropathy and or chronic kidney disease. *BJ Diabetes* 2017;17:160-4

SECTION 6.0 REFERENCES

1. Cosio FG, Kudva Y, Van Der Velde M, et al. New onset hyperglycaemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. *Kidney Int.* 2005;67(6):2415-2421
2. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. *Am J Transplant.* 2003;3(2):178-185
3. Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. *Am J Transplant.* 2003;3(5):590-598.
4. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International Consensus Guidelines. Proceedings of an International Expert Panel Meeting. Barcelona, Spain, February 19, 2003. *Transplantation* 2003;75(10 Suppl):SS3– SS24.
5. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. *Am J Transplant.* 2009;9(Suppl 3):S1–S157
6. Baker R, Jardine A, Andrews P. Renal Association Clinical Practice Guideline on post-operative care of the kidney transplant recipient. *Nephron Clin Prac* 2011;118 Suppl 1:c311-47
7. Sharif A, Hecking M, de Vries AP, Porrini E, Hornum M, Rasoul-Rockenschaub S, Berlakovich G, Krebs M, KautzkyWiller A, Schernthaner G, Marchetti P, Pacini G, Ojo A, Takahara S, Larsen JL, Budde K, Eller K, Pascual J, Jardine A, Bakker SJ, Valderhaug TG, Jenssen TG, Cohn S, Saemann MD (2014) Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. *Am J Transplant* 14(9):1992

8. Baker RJ, Mark PB, Patel RK, Stevens KK, Palmer N. Renal Association Clinical Practice Guideline – Post-Operative Care – February 2017{endorsed by the BTS}. *BMC Nephrology* 2017;18:174

9. Woodle ES, First MR, Pirsch J, Shihab F, Gaber a O, Van Veldhuisen P. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. *Ann Surg* 2008;248(4):564–77

10. Pirsch JD, Henning AK, First MR, Fitzsimmons W, Gaber AO, Reisfeld R, Shihab F, Woodle ES. New-Onset diabetes after transplantation: results from a double-blind corticosteroid withdrawal trial. *Am J Transplant.* 2015;15(7):1982–1990

11. Haller MC, Royuela A, Nagler EV, Pascual J, Webster AC. Steroid avoidance or withdrawal for kidney transplant recipients. *Cochrane Database Syst Rev.* 2016 <https://doi.org/10.1002/14651858.cd005632.pub3>

12. Rostaing L, Cantarovich D, Mourad G, et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. *Transplantation.* 2005;79(7):807-814.

13. Kumar MS, Heifets M, Moritz MJ, et al. Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years. *Transplantation.* 2006;81(6):832-839.

14. Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. *Transplantation.* 2010; 89: 1–14.

15. Luan FL, Steffick DE, Ojo AO. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. *Transplantation.* 2011;91(3):334-341.

16. Pascual J, Royuela A, Galeano C, Crespo M, Zamora J. Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review. *Nephrol Dial Transplant* 2012;27(2):825–32.
17. Serrano OK, Kandaswamy R, Gillingham K, Chinnakotla S, Dunn TB, Finger E, Payne W, Ibrahim H, Kukla A, Spong R, Issa N, Pruett TL, Matas A (2017) Rapid discontinuation of prednisone in kidney transplant recipients: 15-year outcomes from the University of Minnesota. *Transplantation*. 2017;101(10):2590–2598.
18. Thomas O, Wiesener M, Opgenoorth M et al. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial. *Lancet* 2016;388(10063):3006-3016
19. Mourad G, Glyda M, Albano L, Viklicky O, Merville P, Tyden G, Mourad M, Lohmus A, Witzke O, Christiaans MHL, Brown MW, Undre N, Kazeem G, Kuypers DRJ, Advagraf-based immunosuppression regimen examining new onset diabetes mellitus in kidney transplant recipients study i. Incidence of posttransplantation diabetes mellitus in de novo kidney transplant recipients receiving prolonged-release tacrolimus-based immunosuppression with 2 different corticosteroid minimization strategies: ADVANCE, a randomized controlled trial. *Transplantation* 2017;101(8):1924–1934A
20. Pascual J. Steroid avoidance or withdrawal in kidney transplantation. *Curr Opin Organ Transplant* 2011;16(6):600–5.
21. Chakkera HA, Kudva Y, Kaplan B. Calcineurin inhibitors: pharmacologic mechanisms impacting both insulin resistance and insulin secretion leading to glucose dysregulation and diabetes mellitus. *Clin Pharmacol Ther* 2017;101(1):114–120.
22. Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. *Am J Transplant*. 2004;4(4):583-595
23. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC: Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomized trial data. *BMJ* 2005;331:810

24. Kamar N, Mariat C, Delahousse M, et al. Diabetes mellitus after kidney transplantation: a French multicentre observational study. *Nephrol Dial Transplant*. 2007;22(7):1986-1993.
25. Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, Uchida K, Pescovitz MD, Marchetti P, Tuncer M, Citterio F, Wiecek A, Chadban S, El-Shahawy M, Budde K, Goto N. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. *Am J Transplant*. 2007; 7(6):1506–1514.
26. Silva HT, Yang HC, et al Long-Term Follow-Up of a Phase III Clinical Trial Comparing Tacrolimus Extended-Release/MMF, Tacrolimus/MMF, and Cyclosporine/MMF in De Novo Kidney Transplant Recipients. *Transplantation* 2014; 97(6): 636–641.
27. Torres A, Hernandez D, Moreso F et al. Randomized Controlled Trial Assessing the Impact of Tacrolimus Versus Cyclosporine on the Incidence of Post-transplant Diabetes Mellitus, *Kidney International Reports* 2018;(5):1304-1315
28. Wissing KM, Abramowicz D, Weekers L et al. Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with post-transplant diabetes mellitus after renal transplantation. *Am J Transplant*. 2018;18(7):1726-1734
29. Snowsill TM, Moore J, Mujica Mota RE, Peters JL, JonesHughes TL, Huxley NJ, Coelho HF, Haasova M, Cooper C, Lowe JA, Varley-Campbell JL, Crathorne L, Allwood MJ, Anderson R. Immunosuppressive agents in adult kidney transplantation in the National Health Service: a model-based economic evaluation. *Nephrol Dial Transplant* 2017;32(7):1251–1259
30. Sharif A, Shabir S, Chand S, Cockwell P, Ball S, Borrows R. Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. *J Am Soc Nephrol* 2011;22(11):2107– 2118.

31. Karpe KM, Talaulikar GS, Walters GD. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients. *Cochrane Database Syst Rev.* 2017. <https://doi.org/10.1002/14651858.cd006750.pub2>
32. Webster AC, Lee VW, Chapman JR, Craig JC: Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. *Transplantation* 2006;81:1234–1248
33. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. *J Am Soc Nephrol* 2008;19:1411–1418
34. Jinyu Liu, Dong Liu, Lan Zhu et al Efficacy and Safety of Everolimus for Maintenance Immunosuppression of Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials. *PLoS One* 2017;12(1):e0170246.
35. Qazi Y, Shaffer D, Kaplan B et al Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data. *Am J Transplant.* 2017;17(5):1358-1369
36. Vanrentergham Y, Bresnahan B, Campistol J et al Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). *Transplantation* 2011;91(9):976-83.
37. Masson P, Henderson L, Chapman JR et al Belatacept for kidney transplant recipients. *Cochrane Database Syst Rev.* 2014;(11)
38. Vincenti F, Rostaing L, Grinyo J, Rice K et al. Belatacept and Long-Term Outcomes in Kidney Transplantation. *N Engl J Med* 2016; 374:333-343
39. Wen X, Casey MJ, Santos AH, Hartzema A, Womer KL. Comparison of utilisation and clinical outcomes for Belatacept and Tacrolimus based immunosuppression in Renal Transplant Recipients. *Am J Transplant.* 2016;16(11):3202-3211.

40. de Gravy GN, Baan CC, Clahsen-van Groingen MC et al A Randomized Controlled Clinical Trial Comparing Belatacept With Tacrolimus After De Novo Kidney Transplantation. *Transplantation* 2017;101(10):2571-2581
41. Aasebo W, Midtvedt K, Valderhaug TG, et al. Impaired glucose homeostasis in renal transplant recipients receiving basiliximab. *Nephrol Dial Transplant* 2010;25:1289–1293.
42. Prasad N, Gurjer D, Bhadauria D et al. Is basiliximab induction, a novel risk factor for new onset diabetes after transplantation for living donor renal allograft recipients? *Nephrology* 2014;19(4):244-50
43. Morgan R, O’Callaghan J, Knight S, Morris P; Alemtuzumab Induction Therapy in Kidney Transplantation: A Systematic Review and Meta-Analysis. *Transplantation* 2012;93(12):1179–1188
44. Zheng J, Song W. Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients: A systematic review and meta-analysis of randomized controlled trials. *Medicine (Baltimore)* 2017;96(28):e7151

SECTION 7.0 REFERENCES

1. Knowler WC, Barrett-Connor E, Fowler SE, et al., Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002;346:393–403
2. Tuomilehto J, Lindström J, Eriksson JG, et al., Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 2001;344:1343–1350
3. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. *Diabetes Care* 1997;20:537–544
4. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V, Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). *Diabetologia* 2006;49:289–297
5. DeFronzo RA, Tripathy D, Schwenke DC, et al., ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. *N Engl J Med* 2011;364:1104–1115
6. Gerstein HC, Yusuf S, Bosch J, et al., DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. *Lancet* 2006;368:1096–1105
7. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. *Lancet* 2002;359:2072–2077

8. Lean ME, Leslie WS, Barnes AC et al. , Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. *Lancet* 2017 Dec 4. pii: S0140-6736(17)33102-1. doi: 10.1016/S0140-6736(17)33102-1

9. Gürsoy M, Güvener N, Köksal R, et al. Impact of HCV infection on development of posttransplantation diabetes mellitus in renal allograft recipients. *Transplant Proc* 2000;32:561–562

10. Hippisley-Cox J, Coupland C. Development and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study. *BMJ*. 2017;359:j5019. doi: 10.1136/bmj.j5019.

11. Chakkera HA, Weil EJ, Swanson CM, et al. Pretransplant risk score for new-onset diabetes after kidney transplantation. *Diabetes Care* 2011;34:2141–2145

12. Rodrigo E, Santos L, Piñera C, et al. Prediction at first year of incident new-onset diabetes after kidney transplantation by risk prediction models. *Diabetes Care* 2012;35:471–473

13. Costa B, Moratelli L, Silva LB, et al. Body mass index in the first year after kidney transplantation. *Transplant Proc*. 2014;46(6):1750–52.

14. Orazio L, Chapman J, Isbel NM, Campbell KL. Nutrition care for renal transplant recipients: an evaluation of service delivery and outcomes. *J Ren Care*. 2014;40(2):99-106. doi: 10.1111/jorc.12055.

15. Patel MG. The effect of dietary intervention on weight gains after renal transplantation. *J Ren Nutr*. 1998;8(3):137-41.

16. Bzoma B, Konopa J, Chamienia A, Łukiański M, Kobiela J, Śledziński Z, Dębska-Ślizień A. New-onset Diabetes Mellitus After Kidney Transplantation-A Paired Kidney Analysis. *Transplant Proc.* 2018;50(6):1781-1785. doi: 10.1016/j.transproceed.2018.02.119.
17. Wilcox J, Waite C, Tomlinson L, Driscoll J, Karim A, Day E, Sharif A. Comparing glycaemic benefits of Active Versus passive lifestyle Intervention in kidney Allograft Recipients (CAVIAR): study protocol for a randomised controlled trial. *Trials.* 2016;17:417. doi: 10.1186/s13063-016-1543-6.
18. Pedrollo EF, Nicoletto BB, Carpes LS, de Freitas JMC, Buboltz JR, Forte CC, Bauer AC, Manfro RC, Souza GC, Leitão CB. Effect of an intensive nutrition intervention of a high protein and low glycemic-index diet on weight of kidney transplant recipients: study protocol for a randomized clinical trial. *Trials.* 2017;18(1):413. doi: 10.1186/s13063-017-2158-2.
19. Klaassen G, Zelle DM, Navis GJ, Dijkema D, Bemelman FJ, Bakker SJL, Corpeleijn E. Lifestyle intervention to improve quality of life and prevent weight gain after renal transplantation: Design of the Active Care after Transplantation (ACT) randomized controlled trial. *BMC Nephrol.* 2017 Sep 15;18(1):296. doi: 10.1186/s12882-017-0709-0.
20. Osté MC, Corpeleijn E, Navis GJ, Keyzer CA, Soedamah-Muthu SS, van den Berg E, Postmus D, de Borst MH, Kromhout D, Bakker SJ. Mediterranean style diet is associated with low risk of new-onset diabetes after renal transplantation. *BMJ Open Diabetes Res Care.* 2017 Jan 13;5(1):e000283. doi: 10.1136/bmjdr-2016-000283
21. Gomes-Neto AW, Osté MCJ, Sotomayor CG, V D Berg E, Geleijnse JM, Gans ROB, Bakker SJL, Navis GJ. Fruit and Vegetable Intake and Risk for Posttransplantation Diabetes in Renal Transplant Recipients. *Diabetes Care* 2019; 42(9): 1645-1652.

22. Sharif A, Moore R, Baboolal K. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. *Transplantation*. 2008;85(3):353-8. doi: 10.1097/TP.0b013e3181605ebf.

23. Sjöholm K, Sjöström E, Carlsson LM, Peltonen M. Weight Change-Adjusted Effects of Gastric Bypass Surgery on Glucose Metabolism: 2- and 10-Year Results From the Swedish Obese Subjects (SOS) Study. *Diabetes Care*. 2016;39(4):625-31. doi: 10.2337/dc15-1407.

24. Yemini R, Nesher E, Carmeli I, Winkler J, Rahamimov R, Mor E, Keidar A. Bariatric Surgery Is Efficacious and Improves Access to Transplantation for Morbidly Obese Renal Transplant Candidates. *Obes Surg*. 2019 May 27. doi: 10.1007/s11695-019-03925-1.

25. Beaudreuil S, Iglicki F, Ledoux S, Elias M, Obada EN, Hebibi H, Durand E, Charpentier B, Coffin B, Durrbach A. Efficacy and Safety of Intra-gastric Balloon Placement in Dialyzed Patients Awaiting Kidney Transplantation. *Obes Surg*. 2019;29(2):713-720. doi: 10.1007/s11695-018-3574-4.

26. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. *Diabetes Care*. 2004;27(1):155-61.

27. le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjøth TV, Manning LS, Pi-Sunyer X; SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. *Lancet*. 2017;389(10077):1399-1409. doi: 10.1016/S0140-6736(17)30069-7.

28. Werzowa J, Hecking M, Haidinger M, Lechner F, Döller D, Pacini G, Stemer G, Pleiner J, Frantal S, Säemann MD. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled

- clinical trial. *Transplantation*. 2013 Feb 15;95(3):456-62. doi: 10.1097/TP.0b013e318276a20e.
29. Delos Santos R. Efficacy study of sitagliptin to prevent new onset diabetes after transplantation. <https://clinicaltrials.gov/ct2/show/NCT01928199>
 30. Alnasrallah B, Goh TL, Chan LW, Manley P, Pilmore H. Transplantation and diabetes (Transdiab): a pilot randomised controlled trial of metformin in impaired glucose tolerance after kidney transplantation. *BMC Nephrol*. 2019;20(1):147. doi: 10.1186/s12882-019-1321-2.
 31. Gaiffe E, Crepin T, Bamoulid J. *et al*. PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study. *Trials* 2019; 20(375) doi:10.1186/s13063-019-3392-6
 32. Hecking M, Haidinger M, Döller D, Werzowa J, Tura A, Zhang J, Tekoglu H, Pleiner J, Wrba T, Rasoul-Rockenschaub S, Mühlbacher F, Schmaldienst S, Druml W, Hörl WH, Krebs M, Wolzt M, Pacini G, Port FK, Säemann MD. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. *J Am Soc Nephrol*. 2012;23(4):739-49. doi: 10.1681/ASN.2011080835.
 33. Kamar N, Toupance O, Buchler M, *et al*. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. *J Am Soc Nephrol* 2003;14:2092–2098
 34. Vanrenterghem Y, Bresnahan B, Campistol J, Durrbach A, Grinyó J, Neumayer HH, Lang P, Larsen CP, Mancilla-Urrea E, Pestana JM, Block A, Duan T, Glicklich A, Gujrathi S, Vincenti F. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). *Transplantation*. 2011;91(9):976-83. doi: 10.1097/TP.0b013e31820c10eb.

SECTION 8.0 REFERENCES

1. Jenssen T, Hartmann A. Post-transplant diabetes mellitus in patients with solid organ transplants. *Nat Rev Endocrinol* 2019;15(3):172-188.
2. Linder KE, et al. Evaluation of Posttransplantation Diabetes Mellitus After Liver Transplantation: Assessment of Insulin Administration as a Risk Factor. *Ann Pharmacother* 2016;50(5):369-75.
3. Moon JI, et al. Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: Long-term follow up. *Transplantation* 2006;82(12):1625-8.
4. Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. *Nat Rev Gastroenterol Hepatol* 2019;16(6):377-386.
5. Stepanova M, et al. Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis. *BMC Gastroenterol* 2015;15:175.
6. Soule JL, et al. Hepatitis C infection increases the risk of new-onset diabetes after transplantation in liver allograft recipients. *Am J Surg* 2005;189(5):552-557.
7. Morbitzer KA, et al. The impact of diabetes mellitus and glycemic control on clinical outcomes following liver transplant for hepatitis C. *Clin Transplant* 2014;28(8):862-8.
8. Liu FC, et al. Prevalence, predictive factors, and survival outcome of new-onset diabetes after liver transplantation: A population-based cohort study. *Medicine (Baltimore)* 2016;95(25):e3829.
9. Roccaro GA, et al. Sustained Posttransplantation Diabetes Is Associated With Long-Term Major Cardiovascular Events Following Liver Transplantation. *Am J Transplant*, 2018;18(1):207-215.
10. Sharif A, Baboolal K. Diagnostic application of the A(1c) assay in renal disease. *J Am Soc Nephrol* 2010;21(3):383-5.

11. Bhattacharjee D, et al. Utility of HbA1c assessment in people with diabetes awaiting liver transplantation. *Diabet Med* 2018. Nov 26. doi: 10.1111/dme.13870. [Epub ahead of print]
12. Garcia-Compean D, et al. The treatment of diabetes mellitus of patients with chronic liver disease. *Ann Hepatol* 2015;14(6):780-8.
13. Kim HJ, et al. New-Onset Diabetes Mellitus After Heart Transplantation - Incidence, Risk Factors and Impact on Clinical Outcome. *Circ J* 2017;81(6):806-814.
14. Nieuwenhuis MG, Kirkels JH. Predictability and other aspects of post-transplant diabetes mellitus in heart transplant recipients. *J Heart Lung Transplant* 2001;20(7):703-8.
15. Ye X, et al. Risk factors for development of new-onset diabetes mellitus in adult heart transplant recipients. *Transplantation* 2010;89(12):1526-32.
16. Foroutan F, et al. Predictors of 1-year mortality in heart transplant recipients: a systematic review and meta-analysis. *Heart* 2018;104(2):151-160.
17. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. *Lancet* 2007;370(9593):1129-36.
18. Hackman KL, Snell GI, Bach LA. Prevalence and predictors of diabetes after lung transplantation: a prospective, longitudinal study. *Diabetes Care* 2014; 37(11):2919-25.
19. Yusef RD, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. *J Heart Lung Transplant* 2016; 35(10):1170-1184.
20. Klonjtic N, et al. Impact of Diabetes Mellitus on Survival Outcome of Lung Transplant Recipients: An Analysis of OPTN/UNOS Data. *Clin Transpl* 2015;31:43-55.

21. Belle-van Meerkerk G, et al. Diabetes before and after lung transplantation in patients with cystic fibrosis and other lung diseases. *Diabet Med* 2012;29(8):e159-62.
22. Hackman KL, Snell GI, Bach LA. Poor Glycemic Control Is Associated With Decreased Survival in Lung Transplant Recipients. *Transplantation* 2017;101(9):2200-2206.